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NOREPINEPHRINE-INDUCED CARDIOMYOPATHY IN THE RABBIT 
Prolonged exposure of the heart to excessive catecholamines induces a cardiac 
myopathy. Typical lesions include myofibrillar degeneration, leukocyte infiltration 
and focal necrosis. In addition, cardiac dysfunction has been observed after the 
administration of high concentrations of catecholamines. However, alterations in 
diastolic as well as systolic function have not been fully investigated. 
In this dissertation it was hypothesized that cardiac function was impaired 
acutely after a 90 minute, high dose norepinephrine infusion with some functional 
recovery occurring by 48 hours. To further characterize functional alterations, 
myocardial systolic and diastolic function was assessed at three levels of 
norepinephrine-induced injury using the isolated, non-ejecting heart preparation. 
Diastolic and systolic function was impaired acutely after norepinephrine treatment. 
Systolic function improved within 48 hours except in hearts treated with the highest 
dose of norepinephrine. Diastolic function remained depressed. Additionally, 
myocardial responsiveness to ex- and/or /j-adrenergic receptor stimulation was not 
altered acutely or chronically after norepinephrine administration. 
Current research indicates that multiple mechanisms are involved in the 
pathogenesis of catecholamine cardiomyopathy. Toxic metabolites of catecholamine 
autoxidation, possibly acting as membrane oxidants, may have a role in 
catecholamine-induced injury. The myocardial anti-oxidant capacity was increased 
with the administration of a-tocopherol and selenium. This pretreatment however, did 
not protect the rabbit myocardium from norepinephrine-induced injury. 
Alpha-receptor mediated coronary vasoconstriction with resultant ischemia has 
also been proposed as a mechanism of catecholamine injury. Coronary blood flow 
was measured before, during and after a 40 minute, high dose norepinephrine infusion 
(4 µg/kg/min). At 40 minutes, ventricular blood flow was significantly elevated with 
little change in the rate-pressure product. Blood flow returned to control by one hour 
post infusion. 
These results suggest that norepinephrine-induced injury is not produced by 
membrane oxidants or coronary vasoconstriction. The increase in myocardial blood 
flow coupled with a very small change in rate-pressure product also suggests that the 
norepinephrine infusion did not result in a hypoxic insult to the myocardium. 
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CHAPTER I 
INTRODUCTION 
Catecholamines released from sympathetic nerves or adrenal glands are 
important in the normal regulation of cardiac function. Norepinephrine and 
epinephrine increase heart rate, contractile force and myocardial metabolism. In 
pathological situations however, the heart may be exposed to excessive catecholamines 
which subsequently damage the myocardium. Histological examination of hearts 
damaged by catecholamines revealed numerous small areas of necrosis throughout the 
myocardium. This pathology is called catecholamine cardiomyopathy. 
Early investigations indicate that cardiac systolic function is impaired forty-
eight hours after the administration of high concentrations of norepinephrine. 
However alterations in cardiac diastolic as well as systolic function have not been fully 
investigated. In the first study of this dissertation cardiac diastolic and systolic 
function was evaluated at three levels of catecholamine-induced injury. Additionally, 
since myocardial function immediately following exposure to high dose catecholamines 
has not been reported, this study assessed ventricular function acutely after 
norepinephrine-induced injury and at 48 hours. 
Exposure of the heart to catecholamines can reduce myocardial responsiveness 
2 
to /3-adrenergic receptor agonists. In the second study, the ability of norepinephrine 
injured hearts to increase ventricular function with ex- and /3-adrenergic receptor 
stimulation was assessed. It was hypothesized that norepinephrine administration 
would desensitize the /3-receptor, and /3-receptor mediated increases in ventricular 
function would be depressed. In this case, the cx-adrenergic system may be more 
important in increasing cardiac performance after catecholamine-induced injury. 
Current research indicates that multiple mechanisms are involved in the 
pathogenesis of catecholamine-induced injury. Investigators have suggested that the 
autoxidation of catecholamines with the production of toxic metabolites is involved in 
the development of catecholamine cardiomyopathy. These metabolites, which include 
free radicals, may act as oxidizing agents and initiate peroxidation of the cellular 
membranes. In the third study, cx-tocopherol and selenium were administered to 
rabbits over a two week period to increase the antioxidant capacity of the heart. 
Rabbits were then infused with high dose norepinephrine. It was hypothesized that 
this pretreatment would protect the myocardium from norepinephrine-induced injury. 
Alpha-receptor mediated coronary vasoconstriction has also been proposed as 
a mechanism of catecholamine injury. Vasoconstriction of the coronary vasculature 
could cause ischemic injury to the myocardium and produce areas of necrosis. 
Following ischemic injury, myocardial blood flow may not return to normal levels and 
areas of the myocardium may not be perfused. The purpose of the last study was to 
determine if there were perfusion abnormalities associated with a forty minute infusion 
of high dose norepinephrine. 
3 
It is hoped that the research presented in this dissertation will provide 
information regarding the ventricular dysfunction which occurs when a heart is injured 
by catecholamines and may aid in the treatment of patients with pheochromocytoma 
or patients who have suffered cerebral trauma. Identifying acute changes in 
ventricular function of hearts exposed to toxic levels of catecholamines may provide 
a rational for failure of transplanted hearts donated by trauma patients who had a 
massive release of catecholamines from the sympathetic nervous system. 
Additionally, it is hoped that this dissertation gives insight into the mechanisms of 
norepinephrine-induced injury. 
CHAPTER II 
LITERATURE REVIEW 
Under normal physiologic conditions, catecholamines are involved in the 
regulation of cardiac function. The administration of high dose catecholamines 
(256,284,334) or the excessive release of catecholamines from the sympathetic 
nervous system (76,166,185,269,281) is cardiotoxic and results in the development 
of catecholamine-induced cardiomyopathy (269,274). Catecholamine cardiomyopathy 
is defined as an abnormal condition or disease of the heart induced by catecholamines. 
The research presented in this dissertation focuses on the cardiac dysfunction which 
occurs in catecholamine cardiomyopathy, specifically, norepinephrine-induced 
cardiomyopathy and addresses two possible mechanisms of injury. In this chapter, 
background information on catecholamine cardiomyopathy, disposition of 
catecholamines, adrenergic receptor desensitization and proposed mechanisms of 
catecholamine-induced injury will be presented. 
A. CATECHOLAMINE-INDUCED CARDIOMYOPATHY 
Experimentally, catecholamine cardiomyopathy can be induced in vivo or in 
vitro by a variety of catecholamines including epinephrine (EPI) (45,87,88,256), 
4 
5 
norepinephrine (NE) (60,277,284,321,334), and isoproterenol (ISO) 
(60,171,178,269,277,334). Myocardial lesions produced in catecholamine 
cardiomyopathy are characteristic and similar in frogs (41), rats (64,88), rabbits 
(178,256,284), hamsters (127), cats (284), pigs (127), dogs (321,334), monkeys 
(224,228) and humans (269,304,345). Rabbits appear most susceptible to the 
development of cardiac lesions, while rats are more resistent (171,284). 
Characteristic cardiac lesions include: edema, contraction bands, myofibrillar 
degeneration, lipid droplets, hemorrhage, necrosis, leukocyte infiltration, and 
proliferation of fibrous tissue (88,127,263,264,284,321,335). The severity and extent 
of these lesions vary directly with the catecholamine, dose and rate of administration 
(45,127,274). Isoproterenol, particularly in high doses, is most cardiotoxic, able to 
induce massive infarct-like necrosis of the entire ventricular wall (276). Other 
catecholamines and low dose ISO generally produce focal or patchy areas of necrosis 
(15,45). 
In humans, trauma (42), subarachnoid hemorrhage (60,121,269), cerebral 
swelling, brain tumors (60), intracranial infections (269,291) and pheochromocytoma 
(5,49,182,345) elicit an excessive endogenous release of catecholamines. Upon 
postmortem examination, myocardial injury similar to that induced in experimental 
models of catecholamine cardiomyopathy can be identified (265,268). Myocardial 
damage has also been reported in patients after prolonged infusion of NE for the 
treatment of shock (127). Severe cardiac lesions induced by catecholamines may 
impair myocardial function and therefore contribute to organ failure and death. 
6 
1. Gross Anatomical Changes 
Immediately after catecholamine infusion, gross examination of the heart may 
show dilation and/or hemorrhage (171,256,284). Cardiac dilation was moderate to 
extreme depending on the catecholamine and dosage (256,284) and usually was most 
pronounced in the right atrium and right ventricle (284). In the extreme, the heart 
lost its conical shape, the apex was rounded and atria were over-distended (256). NE 
induced necrosis in the canine heart was usually accompanied by hemorrhagic lesions 
in the subendocardium, papillary muscles, cardiac valves and coronary vessels 
(221,237,321). Diffuse and local subendocardial congestion and hemorrhage have 
been observed in rabbit hearts immediately after stopping a 5 hour infusion of 1.2 
µg/kg/min NE (284). Patchy and focal subepicardial and subendocardial hemorrhages 
were found in cats and dogs receiving 2 µg/kg/min NE for 5 hours. Hemorrhages 
were diffuse and extensive in all animals receiving larger doses (284). 
Myocardial edema has been reported following catecholamine injury 
(87,236,256). In the rat myocardium, capillary dilation and increased permeability 
were noted within 15 minutes of subcutaneous high dose ISO (236,276). At lower 
doses, capillary dilation was less frequent and was restricted to areas of injury. In 
these rats, edema was noted throughout the stroma and in areas of severe injury, the 
edema separated muscle fibers. Interstitial and intracellular edema of the myocardium 
has also been reported in other animal models following catecholamine administration 
(87,236,256). 
2. Histological Alterations 
7 
Within minutes of exposure to high levels of catecholamines degenerative 
changes can be observed in myofilaments, mitochondria and the sarcoplasmic 
reticulum throughout the myocardium (16,63,224,275,335). Some myocardial cells 
contained thickened Z lines and contraction bands, areas where sarcomeres were 
hypercontracted (63,86,127,178,275,333,335). Electron microscopic examination 
revealed swelling of the sarcoplasmic reticulum, transverse tubules and mitochondria 
(63,87,88,127,311). Mitochondrial cristae were more closely packed and angulated, 
particularly in EPI-treated animals (41,87,88). Myocardial glycogen was rapidly 
depleted (41,87,88,351,366) and lipid droplets formed between myofibrils and in the 
perinuclear cytoplasm (86-88,127,221,284). Investigators have hypothesized that the 
accumulation of neutral lipids is due to an increased mobilization and uptake 
secondary to increased catecholamine stimulated lipase activity in adipose tissue 
(35,86,88, 149). 
Gradually, some myocardial cells began to recover from the acute insult while 
the areas of injury became localized to isolated or groups of myocytes. In damaged 
muscle cells, the number and extent of contraction bands increased (127). Later, 
characteristic striations and Z lines of cardiac muscle were obliterated (16,276,284). 
In some cells, myofilaments depolymerized and aggregated in bands of granular 
myofilament material (269,276,333,335). Between these aggregates, myofilaments 
torn away from the sarcolemma were occasionally observed (333). By 16 hours, 
mitochondrial cristae were destroyed and replaced with calcium phosphate deposits 
(127,224,269,311). The sarcoplasmic reticulum and transverse-tubules were severely 
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swollen and disrupted (333). Following the appearance of myofilament degeneration, 
nuclei became irregular, increased their staining, then lost their staining capacity 
(269,276). By 72 hours, nuclei were not evident in some cells. Activity of lysosomal 
enzymes and the number of lysosomes in cardiac muscle cells was increased 
throughout the myocardium following catecholamine infusion (87,273). The increase 
in lysosome number was most prominent in cells adjoining necrotic areas where 
lysosomes may play a role in removing dead tissue. In non-necrotic fibers, lipid 
deposition declined after 24 hours and within 3 to 5 days viable myocardial tissue 
contained normal amounts of lipid (88,221). 
Polymorphonuclear leukocytes are scarce immediately following catecholamine 
injury (269,284). Ferrans et al. (87) have shown the presence of various mononuclear 
cells including histiocytes, macrophages, lymphocytes, Anitschkow cells and 
occasionally polymorphonuclear leukocytes and mast cells, 6 to 10 hours after 
catecholamine injection in the rat. Muller (236) also reported moderate infiltration 
of leukocytes and histiocytes in areas of injury in rat hearts after 24 hours with more 
intense infiltration at 48 hours. Similar results have been reported by Bloom and 
Cancilla (16) and Rona et al. (276) at 24 and 48 hours post ISO and by Downing and 
Chen (76) 48 hours after NE infusion. By the third or fourth day, numerous 
histiocytes, macrophages and occasionally lymphocytes and plasma cells were present 
in the interstitium surrounding necrotic myofibers (16,284). Seven days after 
catecholamine administration the majority of necrotic cells had been removed by 
phagocytosis and only a few leukocytes remained (171,269,284). 
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Proliferation of fibroblasts and increased interstitial fibrosis follows necrotic 
injury (321). In rats, fibroblast proliferation was noted 24 and 48 hours after ISO 
treatment (236,276) and a network of thin collagen fibers was formed within 48 hours 
(260). Thicker filaments became entwined in the network and by the eight day 
following catecholamine administration, a dense mesh of collagen fibers had formed 
to encircle muscle and fill intermuscular spaces. Myocardial fibrosis appeared to be 
stimulated by interstitial edema and disruption of fibrillar collagen. Three days after 
NE infusion, connective tissue deposition became apparent in dogs, cats and rabbits 
(284). Within two weeks of catecholamine treatment, fibrous scars were well 
developed and were the only evidence of earlier necrosis and inflammation (16,284). 
B. CARDIAC DYSFUNCTION IN CATECHOLAMINE 
CARDIOMYOPATHY 
Cardiac dysfunction may result from catecholamine-induced lesions. In a 
rabbit model of NE-induced cardiomyopathy, ventricular systolic function was 
depressed in vivo 48 hours after NE infusion (32,198,355). Downing and his co-
investigators reported that contractility, as measured by L V function curves, was 
reduced (198,355). Additionally, the ability of cardiomyopathic hearts to change 
systolic function in response to afterload stress (355) or calcium infusion (98) was 
impaired. Positive inotropic and chronotropic responses were elicited in 
cardiomyopathic hearts (98,198), however, maximal LV stroke volume, LV +dP/dt 
and maximal heart rate were attenuated (32,79,98,198). In these in vivo studies, it 
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is unknown if the endocrine and/or nervous systems are modifying ventricular 
function. Hearts isolated from rats injected with 40 mg/kg ISO showed no change in 
contractile force at 3 hours. Depression in contractile function was noted at 9 and 24 
hours (66). Recently, Chen and Downing (47) have reported that hearts isolated from 
rabbits at the completion of a NE infusion have a decreased ability to increase stroke 
work. Left ventricular diastolic function and acute alterations in other parameters of 
systolic function have not been evaluated. 
In this dissertation it is hypothesized that cardiac function is depressed acutely 
after the administration of catecholamines and significant functional recovery occurs 
within 48 hours. To test this theory, left ventricular diastolic and systolic function 
will be evaluated immediately after a NE infusion and at 48 hours. The isolated 
perfused rabbit heart preparation will be used to measuring ventricular function so 
neural and humoral influences are eliminated. 
C. DISPOSITION OF CATECHOLAMINES 
1. Enzyme Systems 
Catecholamines are metabolized by monoamine oxidase (MAO) and catechol 
O-methyltransferase (COMT) (7,113). MAO is a flavin-containing enzyme tightly 
bound to the outer mitochondrial membrane (339). This oxidase has been found in 
most body organs but it is virtually absent in skeletal muscle, blood plasma and 
erythrocytes (293,331). MAO maintains very low levels of free intracellular 
catecholamines by catalyzing the oxidative deamination of amines to aldehydes 
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(331,332). Two forms of MAO have been identified based on substrate and inhibitor 
specificity (61). MAO-A preferentially deaminates NE and serotonin and has been 
located in adrenergic nerve endings (347) and at extraneuronal sites. MAO-B, found 
only at extraneuronal sites (347), acts on a broader range of amines. The cytosolic 
enzyme COMT is widely distributed in all mammalian tissue (7 ,9). COMT catalyzes 
the transfer of a methyl group from S-adenosylmethionine to catechols in the presence 
of magnesium (9). Substrates for COMT include EPI, NE, and 
dihydroxyphenylalanine (DOPA) (9). 
2. Pathways for Catecholamine Metabolism 
After transport into the cytosol, the pathway for NE metabolism is dependent 
on enzyme availability. In tissue rich in MAO, NE is metabolized to 3,4-
dihydroxyphenolglycol aldehyde (DOPEG-ALD) (Figure 2-1). The aldehyde is 
rapidly metabolized by aldehyde oxidase to 3,4-dihydroxymandelic acid (DOMA) 
(292). COMT converts DOMA to vanillylmandelic acid (VMA). In some tissues, 
the oxidative intermediate DOPEG-ALD is converted to 3,4-dihydroxyphenolglycol 
(DOPEG) then to 3-methoxy-4-hydroxyphenylglycol (MOPEG) by COMT. DOPEG 
is the main deaminated metabolite formed within sympathetic nerves (109). This 
metabolite can readily diffuse out of the neuron into the circulation or be converted 
to MOPEG at extraneuronal sites (8). NE transported into extraneuronal tissues with 
an abundance of COMT, can be converted to its 0-methyl metabolite, 
normetanephrine (NMN) (7). NMN is deaminated to 3-methoxy-4-
hydroxyphenylglycol aldehyde (MOPEG-ALD) (7), then further metabolized to VMA. 
FIGURE 2-1 
METABOLISM OF NOREPINEPHRINE 
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Pathway for norepinephrine metabolism by monoamine oxidase (MAO) and 
catechol O-methyltransferase (COMT). 
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3. Uptake Mechanisms 
In 1965, Iverson (157) identified two distinct mechanisms used for the 
translocation of catecholamines across a cell membrane, uptake1 and uptake:z. These 
uptake mechanisms were saturable, temperature sensitive and obeyed Michaelis-
Menten kinetics (118,158,159). Uptake1 defined the neuronal membrane carrier 
system which transports catecholamines from the extracellular space into neuronal 
tissue (158). 
Uptake1 is inhibited by cocaine (118) and driven by sodium concentration gradient 
across the neuronal membrane (20,106). Once NE is transported into nerve terminals 
by uptake1, it is stored in intracellular vesicles or rapidly degraded by MAO (110). 
Uptake:z, uniquely different from uptake1, transports catecholamines across 
extraneuronal membranes. Uptake:z is corticoid sensitive and depends on the 
potassium concentration gradient and/or resting membrane potential for its function 
(20). Originally uptake:z was thought to operate only at very high extracellular 
concentrations of noradrenaline (157). However, Lightman and Iversen (210) and 
Fiebig and Trendelenburg (90) have clearly demonstrated that extraneuronal uptake:z 
operated effectively at low concentrations of noradrenaline. Within extraneuronal 
tissues, catecholamines are metabolized or bound to intracellular proteins (106). 
4. Tissue and Species Specificity of Inactivation Mechanisms 
After an intravenous catecholamine injection, two phases of removal have been 
demonstrated (357). There is an initial fast phase of tissue uptake, metabolism and 
storage followed by a slow exponential removal. During the slow phase, 
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catecholamines which had been taken up by tissues and not metabolized are slowly 
released back into the circulation (118). The removal of circulating catecholamines 
involves numerous tissues (159,357). Skeletal muscle, vascular smooth muscle, 
erythrocytes and platelets efficiently remove and metabolize circulating catecholamines 
(106,124,206,250,252,293,347). Whitby et al. (357) demonstrated a predominant 
uptake and retention of H3-NE by the heart, spleen and adrenal gland in the cat after 
a 30 minute intravenous infusion. However, H3-normetanephrine in varying 
concentrations was found in all tissues analyzed including the kidneys, salivary glands 
and pancreas. Using an isolated preparation, investigators found the kidney 
metabolized catecholamines and filtered unmetabolized catechols in proportion to the 
glomerular filtration rate (143,300). The lung of the dog, cat and rat efficiently 
removed 30 to 40 % of the NE passing through the pulmonary circulation (4,107). 
Significant amounts of NE were also removed by the intestines, spleen and kidneys 
in these animal models (4,107,196). A single pass through the liver almost 
completely removed (80%) circulating catechols (187). Similarly, the human lung and 
hepatomesentaric circulation have been shown to clear about 70% of total plasma NE 
(81). The relative importance of uptake1 and uptakei for removing catechols varies 
with different tissues and depends on the density of sympathetic innervation and the 
availability of extraneuronal transport mechanism (109,111,159,176,187,210,313). 
The major metabolic route for the inactivation of circulating amines appears 
to be O-methylation (7,33,143,144,188,195,300,332,357). Five minutes after adult 
male mice were injected with H3-NE, 45 % had been metabolized to NMN (357). In 
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humans, urinary analysis after a 30 minute intravenous infusion of radioactive EPI 
showed 65 % O-methylation of the catecholamine and 25 % deamination with the major 
excretory products being VMA and metanephrine (195). Maas and Landis (217) have 
shown that metabolism of circulating NE by human subjects resulted in the urinary 
excretion of free NE, conjugated NE and normetanephrine. Similarly, Goodall and 
Rosen (114) have reported that normetanephrine is the initial metabolite excreted 
during an infusion of NE. Conjugated NE and free NE were also excreted in large 
amounts. After 30 minutes, the major metabolite was VMA. 
The pattern of cardiac uptake and metabolism of plasma catecholamines is 
species specific. Kopin et al. (189) reported the predominant route of non-metabolic 
inactivation of NE in the isolated perfused rat heart was tissue binding or uptake while 
O-methylation was the primary metabolic pathway. In this model, neuronal and 
extraneuronal uptake and metabolism contributed equally to total steady state removal 
of NE (90). NE transported into sympathetic neurons was stored or metabolized. 
There was no extraneuronal accumulation of NE during perfusion with low 
concentrations since metabolism was very pronounced (91,210,338). With exposure 
to high NE concentrations, intracellular COMT became saturated so the unchanged 
amine accumulated within extraneuronal cells (194,210,338). Isolated feline, mouse 
and pigeon hearts formed significant amounts of DOPEG and NMN suggesting 
increased neuronal and extraneuronal uptake and metabolism in response to increasing 
concentrations of noradrenaline (117,165). High concentrations of exogenous NE 
increased the production of DO PEG and DOMA in guinea pig atria (313) and isolated 
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rabbit hearts (117,219). DOPEG, the major oxidized metabolite, was formed 
primarily within the nerve terminals (219,312,313). In guinea pig atria significant 
amounts of DO PEG were also formed in extraneuronal cells (313). DOMA was only 
produced intraneuronally (219,313) and amounted to 25-33% of the oxidized 
metabolites (313). Very little NMN was formed within the rabbit myocardium (117). 
Graefe, Bonisch and Keller have reported that the uptakei mechanism within the rabbit 
heart is poorly developed and suggested that neuronal uptake is the major mechanism 
for catechol removal in this preparation (118). 
5. Conjugation 
Although catecholamines are primarily inactivated by uptake and catabolic 
enzyme systems, inactivation by conjugation with sulfate and glucuronide may be 
physiologically important (7,191,292,353). Kuchel and Buu (191) have suggested that 
the clearance of free NE unaccounted for by neuronal storage, O-methylation or 
oxidation may be due to conjugation. Phenolsulfotransferase, an enzyme which 
transfers a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate to a phenolic 
substrate, sulfoconjugates the 3-0- or 4-O-hydroxyl group of NE, NMN, MOPEG, 
and VMA (2). This cytoplasmic transferase has been found in the liver, adrenals, and 
small intestine. Yet, the presence of NE sulfate within these tissues and the release 
of this conjugate have not been demonstrated (191). Significant conjugation of 
catecholamines has been shown to occur in platelets (2,138,293) and the kidney 
(143,270). Catecholamine conjugates appear to be biologically inactive and protected 
from metabolism by MAO and COMT (271) but they are not inert (229). Merits has 
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reported the urinary excretion of catecholamine metabolites after dopamine sulfate was 
administered to dogs, rats and guinea pigs (229). It may be that sulfoconjugation is 
a reversible process allowing catecholamine sulfates to be hydrolysed to free 
catecholamines. Clinical data suggests that sulfoconjugating systems buffer 
biologically active catecholamines within the circulation (192,193). In some 
pheochromocytoma patients, baseline conjugated catecholamine levels are very high 
(192). During periods of excessive catecholamine release or a hypertensive crises 
conjugated NE and EPI levels increase (192). It appears that the excess circulating 
catecholamines were buffered by enhanced sulfoconjugation. In NE-induced 
cardiomyopathy, high levels of circulating catecholamines may also be buffered by 
sulfoconj ugation. 
6. Autoxidation 
Saturation of transport and enzyme systems by high levels of circulating 
catecholamines, allow more catechols to undergo spontaneous (21,119,302) or 
enzymatic (227,308,342) autoxidation. Ceruloplasmin normally catalyzes the 
cyclization of a small portion of circulating catecholamines to adrenochrome (293). 
During prolonged infusion of high dose NE, ceruloplasmin interacts with more NE 
and may produce abnormally high levels of adrenochrome. Ferritin (Fe+2), an iron 
storage protein, accelerates the non-enzymatic oxidation of catecholamines 
(120,133,231,359). Catecholamine autoxidation produces physiologically active 
metabolites such as adrenochrome, hydrogen peroxide (H20 2)and free radicals 
(21,156,262). If produced in large quantities, these metabolites can impair normal 
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cell function and contribute to the formation of myocardial lesions. 
D. ADRENERGIC RECEPTOR MECHANISMS 
Adrenergic receptors do not directly influence effector enzyme systems or ion 
channels but require coupling proteins, specifically, guanine nucleotide regulatory (G) 
proteins (202,297). G proteins consist of three subunits, a, {3 and 'Y (83,245). The 
{3- and ,..,,-subunits appear to be structurally similar in all G proteins while the a-
subunit shows heterogeneity. The a-subunits binds guanine nucleotides, contains 
guanosine triphosphatase (GTPase) activity and interacts with effector systems when 
guanosine triphosphate (GTP) is bound (83,245). 
Agonist-receptor binding promotes the interaction of the occupied receptor with 
a G protein. The agonist, receptor and G protein complex triggers a conformational 
change in the a-subunit that facilitates the exchange of GTP for guanosine 5'-
diphosphate (GDP) bound to the G protein (136,139). The activated a-GTP subunit 
dissociates from the G protein (83,244) and interacts with effector systems (11,244). 
With GTP hydrolysis, the a-subunit is inactivated and separates from the effector 
enzyme or ion channel (11,136). The inactive a-GDP subunit reassociates with {3-
and ,..,,-subunits to restore the G protein. 
In the adenylate cyclase system, {3-adrenergic receptors are coupled to G 
proteins which stimulate adenylate cyclase, Gs (82). The resultant increase in 
intracellular 3'-5'cyclic adenosine monophosphate (cAMP) initiates a cascade reaction 
and activates specific cytosolic enzymes including protein kinase A. Protein kinase 
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A phosphorylates the calcium channel in cardiac muscle and increases the slow inward 
calcium current (29). The activated a-subunit of Gs also directly modulates this 
calcium channel (29). The greater influx of calcium through the calcium channel 
results in an increased rate and force of contraction of cardiac muscle. 13-Adrenergic 
agonists also augment the pacemaker current increasing the frequency of contraction 
(139). Phosphorylation of phospholamban increases the rate of calcium uptake and 
sequestration into the sarcoplasmic reticulum and increases the rate of relaxation 
(139). The inotropic and chronotropic effects of 13-receptor stimulation have been 
studied in humans (30,167,208), many other animals models including rabbits (27, 79), 
guinea pig (30), rats (306,307) and dogs (213). 
Another G protein couples the a 1-receptor to phospholipase C and regulates 
hydrolysis of phosphoinositol lipids (297). Agonist occupancy of the a 1-receptor 
results in the hydrolysis of phosphatidyl inositol-4,5-bisphosphate to inositol 
triphosphate and diacylglycerol (14,83). Inositol triphosphate mobilizes calcium from 
intracellular stores while diacylglycerol in the presence of calcium activates protein 
kinase C (11,14,139,242). Stimulation of the a 1-adrenoceptor increases the slow 
inward calcium current (83). In 1967, Govier identified a-receptors on the guinea-pig 
atria and demonstrated that stimulation produced a positive inotropic effect (116). 
Since then, positive inotropic responses to a 1-adrenoceptor stimulation have been 
demonstrated in atria, papillary muscles and ventricles of various mammalian species 
including rats (6,19,77,79,239,295), mice (115), guinea pigs (116,197,233,350), 
rabbits (l,10,28,151,255,287,288,349,350), lambs (199), cats (34,266,348) and dogs 
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(78). 
E. RECEPTOR DESENSITIZATION 
Within minutes of exposure to an agonist, cells adapt by decreasing receptor 
responsiveness. This agonist-induced process is called desensitization or 
tachyphylaxis. In the adrenergic receptor system, desensitization results in reduced 
stimulation of adenylate cyclase by {3-adrenergic agonists (136,294,299,352) or 
decreased turnover of inositol phospholipids with a 1-adrenergic receptor stimulation 
(200). Two major patterns of desensitization of adrenergic receptor-coupled second 
messenger systems have been distinguished (136,316). Homologous desensitization 
is characterized by a diminished responsiveness to the desensitizing hormone. If 
exposure to an agonist attenuates the responsiveness of hormones utilizing other 
receptors or non-hormonal activators, the desensitization is heterologous (136). The 
mechanisms of desensitization include receptor phosphorylation, internalization or 
sequestration, and downregulation of membrane receptors (200,202,214). 
1. Receptor Phosphorylation and Uncoupling 
Phosphorylation of cytosolic serine and/or threonine residues on a 1_ and {3-
adrenergic receptors (24,200,202,214,297) decreases the coupling of the receptors to 
G proteins thereby diminishing the activation of effector enzyme systems (13,23,297). 
Exposure of smooth muscle cells to NE rapidly attenuated the agonist stimulated 
hydrolysis of phosphatidylinositol phosphates via the a 1-receptor and decreased 
receptor affinity (200). These functional alterations were closely correlated with a 
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two-fold increase in the phosphate content of the protein receptor. Further 
investigation indicated that protein kinase C, activated after acreceptor stimulation, 
phosphorylated the receptor (24,201). Leeb-Lundberg et al. (24,200) suggested that 
a-receptor phosphorylation was responsible for the desensitization and functional 
uncoupling. {3-Adrenergic desensitization studies have demonstrated selective 
activation of protein kinase A at low concentrations of {3-adrenergic agonists which 
was followed by phosphorylation of {3-receptors (214,297). Resultant phosphorylation 
of the {3-receptors correlated with a decreased sensitivity of the adenylyl cyclase 
response to agonist stimulation (141). At high agonist concentrations, both protein 
kinase A and {3-adrenergic receptor kinase were activated. These kinases 
phosphorylated the {3-receptor (11,203,214,299) and effectively decreased the maximal 
responsiveness of adenylate cyclase to an agonist (141). Furthermore, {3-adrenergic 
receptor kinase, probably working in concert with an "arrestin-like protein" (11), 
inhibited up to 80% of receptor stimulated enzyme activity (12). Benovic et al. (12) 
hypothesized that {3-receptor phosphorylation impaired receptor coupling to G5 • 
2. Internalization 
Chuang and Costa provided the first direct evidence that adrenergic receptors 
are sequestered into an intracellular compartment devoid of adenylyl cyclase and G 
proteins (51,52). These investigators observed a decrease in plasma membrane /3-
receptors number which paralleled an increase in cytosolic receptors after exposure 
of erythrocytes to ISO (51,52). Harden et al. (137) later demonstrated that the 
receptors were sequestered into light vesicles. These results have been confirmed by 
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several laboratories (51,52, 145,200,310). Quantitative studies (230,234,294,310,317) 
have reported that 50-95 % of plasma membrane '3-receptors were internalized with 
exposure to catecholamines. The mechanism of sequestration remains to be elucidated 
but may involve the endocytosis of receptors (52,112,145,257). Phosphorylation 
appears to promote the internalization of '3-receptors (52,297) but does not appear to 
be essential (48,214,317). In contrast, Leeb-Lundberg et al. (200) reported that 
internalization of the a 1-adrenoceptor required both receptor phosphorylation and 
agonist occupancy. 
Within the light vesicles, receptors are dephosphorylated (13,299) and retain 
their structural and functional integrity (54,318). Upon removal of the agonist, 
sequestered receptors are recycled back to the plasma membrane where they can 
interact with G proteins and activate their second messenger system (299,318). 
Mukherjee et al. (235) have demonstrated the complete recovery of plasma membrane 
'3-adrenergic receptors in frog erythrocytes after the agonist was removed. Similarly, 
Doss et al. (75) have also shown that a 95 % loss in plasma membrane receptor 
number of preconfluent cultures of astrocytoma cells was completely reversible within 
48-72 hours after removal of the agonist. In both studies (75,235), receptors were 
recovered even when protein synthesis was blocked. 
The contribution of receptor internalization in the desensitization process is still 
being investigated. Some investigators have proposed that receptor phosphorylation 
is the mechanism of desensitization (23,25,200,298,299,319,352) while receptor 
internalization is a secondary process (25,200,310,319). Waldo et al. (352) have 
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shown that agonist induced uncoupling of human astrocytoma tJ-receptors from 
adenylate cyclase preceded internalization. When sequestration was inhibited, 
uncoupling still occurred (352). Similar results were reported by Homburger et al. 
(152) in cultured glioma cells and by Bobik et al. (18) in chick embryo cardiac cells. 
In contrast, it has been reported that internalization is not dependent on receptor 
phosphorylation and contributes significantly to cellular desensitization (51,214,317). 
The sequestration response to ISO is not altered when phosphorylation sites on the 
carboxyl terminus of hamster tJ-adrenergic receptors are removed (317). Lohse et al. 
(214) have reported that sequestration resulted in a 20-30 % decrease in the tJ2-
receptor-stimulated adenylyl cyclase activity in human epidermoid carcinoma A431 
cells exposed to high agonist concentrations while kinase activities were inhibited. 
The apparently conflicting results may indicate that receptor sequestration as a 
mechanism of desensitization is species and/or cell line specific. Alternately, it may 
be that sequestration normally removes phosphorylated receptors from the cell surface 
for dephosphorylation and recycling but at high agonist concentrations becomes a 
mechanism of desensitization. 
3. Long Term Regulation 
Longer term desensitization may involve additional mechanisms. Hausdorff 
et al. (141) suggested that modification of G proteins or adenylyl cyclase may occur 
with prolonged exposure to an agonist. Katada et al. (175) reported that the 
dissociated a-subunit of purified G; protein is a substrate for protein kinase C and its 
phosphorylation altered the function of the a-subunit. Phosphorylation of the purified 
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catalytic unit of adenylyl cyclase by protein kinase A and C has also been reported 
(11). However, in vivo studies are needed to elucidate the physiologic significance 
of G protein or cyclase modification. Down-regulation of receptors, ie, the loss of 
total receptor binding sites from a cell, has been demonstrated in some models of 
desensitization (136,152,319). The total number of /3-adrenergic receptors was 
reduced 45.4% in glioma cells after a 3 hour incubation with ISO (152). Confluent 
cultures of astrocytoma cells recovered only 60 to 70% of the /3-receptors following 
the removal of ISO (75). Su et al. (319) also reported /3-receptor loss in 1321Nl 
astrocytoma cells, S49 lymphoma cells and HC-1 hepatoma cells with long term 
incubation with ISO. In these cell lines, complete recovery of the plasma membrane 
receptors required protein synthesis ( 11, 75). The data suggests that chronic exposure 
to an agonist results in receptor degradation and loss from the cellular pool. 
4. Desensitization of Cardiac Adrenergic Receptors 
Cardiac desensitization of adrenergic receptors has been demonstrated in a 
number of experimental models (94,177,222,223,337,340). Kirkendol and Woodbury 
(180) demonstrated a tolerance in dogs within 15 minutes of a 60 minute intravenous 
infusion of NE (2.5 µg/kg/min). A failure of NE to maintain the increased blood 
pressure and contractile force was noted. With further investigation it was concluded 
that the heart was the primary site of tachyphylaxis (180). Kaumann and Bimbaumer 
(177) have reported decreased inotropic and chronotropic responsiveness of kitten atria 
to isoprenaline after 3 hour exposure to the agonist. Chick ventricular tissue 
preincubated with ISO for 30 minutes also showed diminished the inotropic response 
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to the agonist while the responsiveness to extracellular calcium was not altered (222). 
{J-Adrenergic receptor number and affinity was not changed but the ability of ISO to 
stimulate adenylate cyclase was reduced by 29 % . Further investigation showed no 
abnormality in the cyclase (222). Cultured chick embryo ventricular cells exhibited 
a similar concentration and time dependent {J-receptor desensitization with a 30 minute 
exposure to ISO (223). 
Chang et al. have reported a selective desensitization of rat cardiac {J-receptors 
following prolonged in vivo infusion of 400 µglkglhr ISO or 200 µglkglhr NE ( 44). 
Decreased inotropic and chronotropic responsiveness of the right and left atria to ISO 
was apparent by 2 hours of catecholamine infusion. {J-Receptor density was not 
significantly decreased until seven days of catecholamine infusion. In this model, the 
cardiac ai-receptor was not desensitized by the mixed al{J agonist NE. In contrast 
Corder et al. (62) demonstrated a reduction in {J-receptors at 9 hours post ISO 
injection (40 mg/kg) and a reduction in a-receptors by 24 hours. The disparity of 
these studies may be related to the specific catecholamine administered or the dosage. 
Isoproterenol in doses high enough to produce necrosis did not change basal 
activity of adenylate cyclase in the rat myocardium but depressed adenylate cyclase 
response to ISO stimulation in the necrotic left ventricular tissue (286). Schulze et 
al. suggested the damage in the necrotic regions destroyed the coupling of the 
receptor, G protein and the enzyme (286). However, additional research suggested 
that the G protein may be altered by high dose catecholamines. Tse et al. (340) 
reported a decreased ventricular basal and NaF-stimulated adenylate cyclase activity 
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after chronic ISO treatment. Corder et al. (62) showed a decreased EPI-, NaF- and 
Gpp(NH)p-stimulated adenylate cyclase activity within 3 hours of a high dose ISO 
injection while basal activity was not altered. The attenuated responses to Gpp(NH)p 
and NaF-stimulation indicated a defect in the G protein. Adenylate cyclase response 
to forskolin, a direct stimulator of the enzyme, needs to be measured to rule out 
changes in the enzyme itself (62). 
If high levels of circulating catecholamines uncouple the /3-receptor from its 
G protein or alter the function of Gs, /3-receptor mediated increases in ventricular 
function should be depressed acutely with NE-induced injury. Chang et al. (44) found 
that the rat cardiac a-adrenergic receptor was not desensitized by a prolonged infusion 
of high dose NE. In this case, the a-adrenergic system may be more important in 
increasing cardiac performance in norepinephrine cardiomyopathy. To test this 
hypothesis, the functional responsiveness of the left ventricle to a- and /3-adrenoceptor 
stimulation will be assessed immediately after a 90 minute NE infusion and at 48 
hours post-infusion. 
F. SUGGESTED MECHANISMS OF CATECHOLAMINE-INDUCED INJURY 
Experimental research indicates that multiple mechanisms are involved in the 
pathogenesis of catecholamine-induced cardiac injury. 
1. Calcium Overload Theory 
In 1971, Fleckenstein demonstrated an increase in calcium influx into ISO-
treated hearts and suggested that calcium overload was a mechanism of catecholamine-
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induced injury (93). It was hypothesized that excessive calcium influx into myocardial 
cells by ~-adrenergic receptor stimulation induced calcium dependent A TPases and 
increased the utilization of high energy phosphates stores. High intracellular calcium 
impaired mitochondria function and decreased oxidative phosphorylation and ATP 
production. The subsequent deficiency in high energy phosphates resulted in the 
development of myocardial lesions. Further investigation did not totally support this 
hypothesis. Opie et al. (153,249) found epinephrine induced the release of myocardial 
lactate dehydrogenase without a significant change in tissue ATP. Simply, myocardial 
damage occurred without a deficiency in ATP. Other investigators (204) reported a 
decrease in high energy phosphates 2 hours post ISO injection. At 2 hours, significant 
cellular injury had already occurred. These studies indicate that ATP deficiency is 
not a primary mechanism of catecholamine injury. It was still apparent however, that 
increased intracellular calcium was intricately involved in the etiology of 
catecholamine injury (17,249) since calcium overload of myocardial cells had been 
demonstrated repeatedly with the administration of high dose catecholamines 
(17,68, 178,249) and calcium channel blockade reduced the deleterious effects of 
catecholamines on the heart (53,178,314). 
During normal cell functioning, calcium is extruded from the cell by the 
sarcolemmal sodium-calcium exchange and calcium pump or removed by uptake into 
the sarcoplasmic reticulum and mitochondria (68,140). In catecholamine 
cardiomyopathy, removal of calcium from the cytosol is impaired. Makino et al. 
(220) showed a depression in the activity of the sarcolemmal sodium-calcium exchange 
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in rat hearts 3, 9 and 24 hours after ISO treatment. Calcium pump activity was 
reduced at 24 hours (67) but sodium-potassium A TPase activity was not affected 
(220). With these experimental results, Makino et al. (67,220) suggested that the 
reduced ability to remove calcium through the sarcolemmal sodium-calcium exchange 
and calcium pump contributed to the intracellular calcium overload seen in 
catecholamine-induced injury. Calcium uptake by the sarcoplasmic reticulum was also 
altered. Microsomal uptake of calcium was elevated 3 hours after ISO injection in 
rats but depressed at 24 hours (253). Calcium pump activity of rabbit microsomes 
was also decreased with ISO treatment (346). This decrease in sarcoplasmic calcium 
uptake appears to be associated with the loss of the calcium A TPase transport protein 
from the sarcoplasmic reticulum membrane (253). These studies indicate that 
impaired removal of calcium from the cytosol by sarcolemmal and sarcoplasmic 
reticulum mechanisms coupled with increased influx of calcium may contribute to the 
intracellular calcium overload seen after the administration of high dose 
catecholamines. 
Elevated intracellular calcium activates hydrolytic enzymes which may 
contribute to membrane defects seen in catecholamine injury (68). Calcium overload 
can activate intracellular proteases and release lysosomal enzymes (68,248). 
Phospholipases which release free fatty acids from the membrane and stimulate the 
generation of toxic intermediates of arachidonic acid metabolism are also activated 
(26,186,282). Arachidonic acid intermediates initiate lipid peroxidation of 
intracellular and sarcolemmal membranes which can further increase intracellular 
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calcium (282). Several investigators have also shown that the rate of lipoperoxidation 
was enhanced in the presence of calcium (161,168,170). 
Uncoupling of oxidative phosphorylation has been observed in mitochondria 
from rats treated with EPI, NE or ISO (309). The decrease in ATP formation was 
not a direct effect of these amines since catecholamines applied to normal 
mitochondria in vitro did not affect oxidative phosphorylation. At 9 and 24 hours post 
ISO treatment, a time when myocardial injury has already been identified, 
mitochondrial uptake of calcium increased (253). Elevated mitochondrial calcium was 
associated with depressed respiratory activity and decreased ATP production (65,68). 
Accumulation of long chain fatty acids within the cell and products of catecholamine 
autoxidation also uncouple oxidative phosphorylation and reduce ATP production 
(149). The subsequent depletion of high energy phosphates may then contribute to 
cellular necrosis. 
2. Relative Hypoxia 
Rona et al. (276) proposed that relative hypoxia, due to imbalance between 
oxygen supply, and demand caused ISO-induced myocardial necrosis. In most tissue 
oxygen supply can be augmented by increasing oxygen extraction from arterial blood 
and/or increasing blood flow. In the heart, extraction is near maximal at rest so 
increased oxygen supply must come through an augmented blood flow. Rona and his 
co-investigators observed an increase in systolic pressure then a decrease toward 
control during sustained catecholamine infusion while coronary vascular resistance 
changed very little. Since coronary flow was dependent on systolic pressure, it was 
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concluded that the oxygen delivery was not adequate resulting in hypoxia and 
myocardial necrosis. Subsequent research did not support this hypothesis. since 
catecholamine injury occurred where oxygen supply and/or coronary flow was 
adequate (153,178). 
3. Microcirculatory Changes 
In the early 1960's, Handforth (135) observed a reduction in flow to the inner 
areas of the hamster left ventricular wall after ISO, even prior to the development of 
edema or necrosis. He suggested that impaired perfusion was due to local 
vasoconstriction or shunting of blood to bypass the endocardium. Later, Collins and 
Billings (56) reported that ISO reduced perfusion of subendocardium in rat left 
ventricle. Similar changes in flow have been reported in rabbits and dogs in response 
to NE (301,354). Simons and Downing (301) demonstrated augmented coronary 
blood flow after 3 minutes of NE infusion in the rabbit and a return to control at 10 
minutes. After 40 minutes of NE infusion, coronary vascular resistance was increased 
and myocardial blood flow sharply declined. a-Adrenergic receptor blockade 
prevented the decrease in blood flow and increase in vascular resistance and 
minimized histological damage. These studies suggest that coronary vasoconstriction 
during catecholamine infusion may decrease endocardial blood flow and contribute to 
catecholamine-induced injury. 
Haft et al. (129) reported that aspirin and dipyridamole, inhibitors of platelet 
aggregation, protected the canine myocardium from BPI-induced necrosis. 
Thrombocytopenia or inhibition of platelet aggregation strongly reduced the number 
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and area of cardiac necrosis induced by ISO in the rat (173). Electron micrograph 
analysis revealed platelet aggregates within small vessels of the myocardium 
immediately following a prolonged NE infusion in the dog (130) or ISO injection in 
the rat (128). These investigators suggested that intravascular platelet aggregation had 
a role in the etiology of catecholamine-induced cardiac necrosis. In contrast, other 
investigators have not observed platelet aggregates in the myocardium after 
catecholamine administration. Moschos et al. (232) did not find 51Cr-prelabelled 
platelets in the canine heart after a systemic infusion of toxic levels of EPI. Similarly, 
platelet thrombi were not found in rabbit hearts after high dose NE infusion (76). 
4. Metabolites of Catecholamine Autoxidation 
It has been proposed that products of catecholamines oxidation are responsible, 
in part, for catecholamine cardiotoxicity. Yates and Dhalla have shown decreased 
cardiac function and ultrastructural damage in isolated rat hearts perfused 40-50 
minutes with spontaneously oxidized ISO (69,362). Similar concentrations of fresh 
ISO increased left ventricular function and produced no structural damage. Perfusion 
of rat hearts with purified adrenochrome induced ultrastructural changes and 
contractile failure (363). Mitochondrial and sarcotubular swelling, intracellular 
edema, hypercontraction of myofibrils and partial separation of intercalated discs 
became apparent within 5-10 minutes after the administration of intravenous 
adrenochrome (4-32 mg/kg) to rats (303). These ultrastructural lesions in hearts 
subjected to oxidized ISO or adrenochrome were qualitatively identical to those seen 
after the administration of high dose catecholamines in vivo (334). Further 
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investigation indicated that oxidation products of catecholamines, m addition to 
adrenochrome, damage the myocardium and may be involved in the genesis of 
catecholamine cardiotoxicity (162,305). 
Decreased calcium uptake activity has been reported for microsomal 
membranes from hearts damaged by oxidized ISO while microsomal A TPase activity 
was not modified (69). Changes in membrane integrity, indicated by sarcoplasmic 
reticular swelling, may have uncoupled calcium transport from ATP hydrolysis 
(69,146). Mitochondrial calcium transport and ATPase activity were not effected by 
oxidized ISO but oxidative phosphorylation was depressed (69). Exposure to 
adrenochrome alters membrane ATPases and calcium transport of the sarcolemma, 
sarcoplasmic reticulum and mitochondria. Takeo et al. (322) reported a reduction in 
sarcolemmal sodium-potassium ATPase activity after hearts were perfused with 
adrenochrome. Additionally, calcium uptake by microsomal and mitochondrial 
membranes was depressed (323,324). Calcium ATPase activity was not affected by 
low dose adrenochrome. At higher concentrations, this ATPase activity was inhibited 
in microsomes, the sarcolemma and mitochondria (322-324). Adrenochrome also has 
been shown to be a potent inhibitor of oxidative phosphorylation (69,254). 
In contrast, administration of adrenochrome (10 mg/kg) had no effect on the 
myocardium of embryonic chicks while oxidized isoprenaline caused severe damage 
(162). Wheatley et al. (356) have reported that rat hearts perfused with 10-6 to 104 
M adrenochrome for 45 minutes had no myocyte damage. However, perfusion with 
104 M adrenochrome for 120 minutes induced myocardial damage and contractile 
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failure. These investigators proposed that 104 M adrenochrome was not a physiologic 
concentration and therefore irrelevant to the pathogenesis of catecholamine 
cardiomyopathy (356). However, concentrations of oxidized metabolites within the 
myocardium have not been reported. The disparity of results may be due to the 
difference in composition of the oxidized agent. Chromatographic analysis revealed 
a significant differences in the composition of spontaneously oxidized isoprenaline, 
purified adrenochrome and commercially obtained adrenochrome (162). 
Catecholamine autoxidation also creates superoxide anion radicals (02·) 
(21,92,119,142,227,262,302,308,342) hydrogen peroxide (119,231). Superoxide 
anion, as well as subsequently formed free radicals, are highly reactive molecules 
containing a single unpaired electron in its outer shell (74,218). These radicals cause 
tissue damage by reacting with polyunsaturated lipids within membranes (40,267), 
nucleotides in DNA, or sulfhydryl bonds in proteins (218). Superoxide anion and 
hydrogen peroxide directly damage cells but the primary mechanism of toxicity 
appears to be the generation of more reactive species (43,133,163). In reactions 
secondary to superoxide generation, singlet oxygen, a spin altered form of oxygen 
(92), is produced (58,179,238). Singlet oxygen reacts very rapidly with unsaturated 
fatty acids within membranes to yield lipid peroxides (55,58, 179). Lipid peroxides 
within biological membranes can change membrane fluidity, permeability and 
function. Alternately, superoxide may dismutate to hydrogen peroxide (100) and 
generate hydroxyl radicals via Fenton chemistry (57,132). The highly reactive 
hydroxyl radical usually initiates a radical chain reaction. If produced in the 
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immediate vicinity of phospholipid membranes, hydroxyl radicals initiate peroxidation 
by abstracting hydrogen atoms from unsaturated bonds of membrane lipids 
(43,95, 133,174,261,267,302,330). Normally, free radicals are scavenged or instantly 
trapped by antioxidants (74). Accumulation of free radicals is dependant on the 
capacity of enzymatic and non-enzymatic antioxidant systems within the tissue (285). 
In conditions where the antioxidant capacity is overwhelmed, free radical production 
may result in lipid peroxidation and subsequent alterations in membrane structure, 
enzyme inactivation, and decreased energy production. 
5. Changes in Membrane Permeability 
Rona et al. (275) reported an increased sarcolemmal permeability 90 minutes 
post ISO injection in rats. Horseradish peroxidase reaction products were deposited 
on myofilaments of damaged cells and cells which appeared ultrastructurally intact. 
Later peroxidase reaction products were identified within mitochondria. Subsequently, 
Boutet et al. (22) demonstrated horseradish peroxidase within rat cardiac myocytes as 
early as 10 minutes after NE infusion and at 60 and 90 minutes post ISO. Increased 
membrane permeability was also noted in isolated rabbit hearts after a 60 minute 
perfusion with ISO (336). More recently, Yunge et al. (365) reported horseradish 
peroxidase within cardiac myocytes and irregular tears in sarcolemmal membranes of 
some myocytes 10 and 60 minutes after subcutaneous ISO. Similar results were 
obtained in isolated rat hearts perfused with ISO or oxidized ISO (365) indicating a 
role for oxidized metabolites in ISO-induced injury. In agreement with these 
histological studies, Schenk et al. (283) demonstrated a progressive dose related 
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increase of the cardiac isoenzyme of lactate dehydrogenase the plasma of dogs within 
15 minutes of a NE infusion. The presence of the heart isoenzyme in plasma 
indicated damage to the cardiac sarcolemma with subsequent release of this 
intracellular enzyme. These studies suggest that alterations in cardiac sarcolemmal 
permeability is an early event in catecholamine-induced injury. 
The increased membrane permeability seen with high dose catecholamines may 
change electrolyte distribution in the myocardium. Lehr et al. (205) and Nirdlinger 
and Bramante (241) found significant alterations in electrolyte content and distribution 
in rat hearts after catecholamine injection. Magnesium and inorganic phosphate were 
depleted, sodium and calcium content increased. Intracellular calcium was 
sequestered by mitochondria at the expense of energy production (68). Other 
investigators found ISO treatment increased cardiac sodium, water and chloride but 
decreased potassium (311). In fact, catecholamines stimulated a rapid outward 
movement of intracellular potassium and a high potassium diet afforded some 
protection to ISO-induced injury (171). These electrolyte shifts were correlated with 
swelling and disintegration of mitochondria and enlargement of the sarcotubular 
system in cardiac myocytes. 
6. Lipid Peroxidation 
Lipid peroxidation is initiated by the abstraction of a hydrogen ion from an 
unsaturated lipid and the formation of a lipid free radical, L' (Reaction [ 1]) (38,174). 
With the rich supply of oxygen within membranes, the lipid radical is quickly oxidized 
to a peroxyl radical (LOO) (Reaction [2]). This peroxyl radical can attack another 
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unsaturated lipid producing a hydroperoxide (LOOH) and a new lipid free radical 
(Reaction [3]), thus establishing a chain reaction. Hydroperoxides cari later 
decompose to peroxy and alcoxy (LO) radicals (Reaction [4]) which initiate other 
chain reactions (Reactions [3] and [5]). Without an antioxidant within the membrane, 
lipid peroxidation is propagated until two lipid radicals react together to form 
nonreactive molecular products (125). By a chain reaction, many unsaturated lipids 
can be oxidized for each lipid radical formed (38,226,360). 
[l] 
[2] 
[3] 
[4] 
[5] 
LH-+L 
L + 0 2 -+ LOO-
LOO + LH -+ LOOH + L· 
LOOH -+ LOO· or LO· 
LO· + LH -+ LOH + L· 
Lipid peroxidation changes membrane characteristics. Membrane permeability 
is increased. Rat brain synaptosomes rapidly accumulated calcium after peroxidation 
was stimulated (26). Increased calcium uptake was highly correlated with the 
formation of products of peroxidation. Deferoxamine, a lipid peroxidation inhibitor, 
blocked the formation of products of lipoperoxidation and uptake of calcium into 
synapt0somes after exposure to peroxidizing agents. Calcium channel blockers did 
not affect calcium uptake by synaptosomes with peroxidation. Using oleic and linoleic 
acid ufasomes, Hicks and Gebicki (147) demonstrated a significant increase in glucose 
leakage after peroxidation of approximately 4-5 % of membrane lipids. Lipid 
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peroxidation in cardiac sarcoplasmic reticulum vesicles induce the complete release 
of calcium (209). Calcium leakage was mediated by the formation of- lipid 
hydroperoxide channels (360) in the lipid phase of the sarcoplasmic membranes and 
in the Iipoprotein complex of calcium ATPase (169). Calcium leakage from the 
sarcoplasmic vesicles is blocked by a-tocopherol (209). By disturbing the normal 
bilayer arrangement of membrane lipids, lipid peroxidation changed membrane 
permeability. 
Decreased membrane fluidity (99) and increased rigidity of phospholipid 
bilayers (72) have been reported after lipid peroxidation. Rice-Evans and Hochstein 
(272) demonstrated an increase in lipid microviscosity with peroxidation of membrane 
lipids and suggested lipid-lipid interaction and lipid packing density increase while 
lipid-protein interactions decrease (296). These modifications of membranes structure 
have been correlated with alteration in membrane bound enzyme function (72). In 
isolated mitochondria, oxidative phosphorylation was uncoupled with lipoperoxidation 
(155,326). The degree of peroxidation which changed membrane fluidity was similar 
to that which alters mitochondrial function (72). Lipid peroxidation also damaged 
membrane proteins (326) and inactivates enzymes (43,172,330). Hydrogen ion 
abstraction by lipid peroxy radicals altered protein structure (326). Damaged proteins 
are able to cross-link with other proteins or phospholipids to form polymers 
(160,272). Malondialdehyde, a degradation product of peroxidized lipids (226,261), 
may facilitate amino group cross-linking within the membrane (108,160,174,272,326). 
Levin et al. reported cytochrome P450 breakdown during lipid peroxidation (207). 
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Random damage to cytochromes a + a3 , b, and c + c1 has also been reported (326). 
Slight accumulation of lipoperoxidation products in cardiac microsomes uncoupled 
ATP hydrolysis from calcium transport and completely inhibited calcium transporting 
ability (170). The antioxidant a-tocopherol prevented accumulation of peroxidation 
products and protected microsomal membrane calcium transport. Inactivation of 
mitochondrial and microsomal enzymes (261,326,358) and membrane ATPases (272) 
also closely parallel lipid peroxidation. Alterations in enzyme function may be due 
to protein damage and subsequent polymerization or due to changes in the 
phospholipid microenvironment (123). 
G. CELLULAR ANTIOXIDANTS 
The human body has multiple lines of defense against oxidizing agents and free 
radicals encompassing enzymes systems and small molecular weight molecules with 
antioxidant capabilities. These antioxidant defense mechanisms include a-tocopherol 
and glutathione peroxidase. 
1. a-Tocopherol 
Alpha-tocopherol, the principle antioxidant constituent of vitamin E, is found 
in plasma and intracellular membranes of throughout the body including cardiac 
myocytes (122,163,218,226,247). The basic structure consists of a hydroxylated ring 
system and an isoprenoid side chain (240). The aromatic ring or chromanol group of 
a-tocopherol is oriented toward the membrane surface and a hydrophobic phytyl side 
chain is buried within the hydrocarbon region (38). This structure allows a-
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tocopherol to be an effective scavenger of lipid free radicals (37,39,70), superoxide 
anion radicals (02·") (100,102), hydroxyl radicals (HO') (100,101,225), and singlet 
oxygen (102) (55,84,96,97,315) as well as a stabilizer of biological membranes 
(80,215). 
The presence of fat-soluble antioxidants which inhibit or terminate free radical 
reactions of unsaturated lipids is essential to membrane integrity (154,226). Alpha-
tocopherol, a principle defense against lipoperoxidation (102,329), is an effective 
chain-breaking antioxidant (38,327). It does not prevent the initiation of lipid 
peroxidation (148,360) but traps the propagating lipid radicals thereby terminating the 
autoxidizing chain reactions (Reaction [6]) (37 ,39, 102,150,327,329). The resulting 
phenoxy radical of a-tocopherol (aT-O') is resonance stable and does not continue the 
chain reaction (38). The a-tocopherol radical can be destroyed by reaction with a 
second peroxyl radical (Reaction [7]) (38) or be reduced by ascorbic acid 
(38,102,225,251). Fukuzawa et al. (99) reported that one molecule of a-tocopherol 
prevented peroxidation of approximately 100 polyunsaturated fatty acid molecules. 
[6] 
[7] 
LOO· + aT-OH - LOOH + aT-0· 
LOO· + T-0- - unreactive products 
The antioxidant capability of a-tocopherol has been demonstrated in vitro and 
in vivo (89,102,164,181). Lipid oxidation in egg yolk phosphatidylcholine liposomes 
was inhibited after a critical concentration of a-tocopherol was present (102). As a-
tocopherol concentration increased above this critical level, peroxidation decreased 
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then stopped entirely although the tocopherol was still being oxidized. At this point 
a-tocopherol competed successfully with oxygen for lipid radicals. The efficacy of 
a-tocopherol is dependent on the membrane concentration (360). 
Having membranes rich in polyunsaturated lipids and numerous catalysts of 
lipid peroxidation, mitochondria are highly susceptible to oxidation damage (326). a-
Tocopherol, normally present on the inner mitochondrial membrane (226), has been 
associated with enzymatically active lipoprotein complexes of the electron transport 
system (85,247,289). Mitochondria from a-tocopherol deficient rabbit hearts had 
depressed function, increased lipoperoxidation and enhanced production of superoxide 
anion by electron transport enzyme systems (123). The increased formation of 
superoxide anion was beyond the neutralizing capacity of the superoxide dismutase 
(227) and resulted in loss of polyunsaturated lipids from mitochondrial membranes 
(226). Further lipid peroxidation resulted in the swelling, lysis and disintegration of 
membranes from isolated mitochondria (326). The presence of a-tocopherol in 
membranes of the cardiac mitochondria protected them from oxidative damage and 
membrane deterioration (123,326). Reduced cytochrome levels in liver mitochondria 
and decreased oxidative ability of the mitochondria have been reported in vitamin E 
deficient rats (289). With vitamin supplementation cytochrome levels and oxidative 
ability of the mitochondria were restored. Vitamin E may protect the membrane 
bound proteins from damage maintaining normal enzyme concentration within the 
membrane. 
Increased susceptibility to lipid peroxidation is associated with a-tocopherol 
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deficiency (240,320). Janero and Burghardt (164) have shown phospholipid damage 
characterized by acute onset and rapid progression in cardiac membranes from rats 
with a 3-fold lower a-tocopherol content compared to control rat hearts. This relative 
a-tocopherol deficiency increased the susceptibility of the myocardial lipids to 
peroxidative injury and reduced the efficacy of other antioxidant interventions. 
Similar results have been reported for the mouse myocardium (280). Rats fed diets 
with large amounts of unsaturated fats had increased malonaldehyde in bone marrow, 
heart and spleen compared to rats fed normal diets (330). Peroxidation was 
proportional to polyunsaturated fatty acids content and inversely related to a-
tocopherol (134,330). 
Experiments of Lucy and Diplock (71,215,216) indicated that a-tocopherol 
modulated the structure and permeability of the phospholipid bilayer of biomembranes. 
Studies using monolayers of phospholipids and a-tocopherol demonstrated a molecular 
interaction between a-tocopherol and unsaturated phospholipids but gave no evidence 
of tocopherol interacting with saturated lipids (216). Ultraviolet absorption spectra 
and flourometric assays also suggested that a-tocopherol forms complexes with free 
fatty acids in membrane systems (80). Using molecular modeling, Lucy and Diplock 
(215) proposed a dynamic interaction between a-tocopherol and phospholipids 
containing arachidonyl residues or similar fatty acyl chains. Specifically, methyl 
groups of the phytyl side-chain of a-tocopherol move into pockets created by cis 
double bonds of fatty acyl chains. Remaining methylene groups in the backbone of 
the phytyl and fatty acyl chains interact through Van der Waals forces, stabilize the 
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membrane and preserve the integrity of cell membranes (80,215). Additionally, 
Urano and Matsuo (341) reported that the chromanol moiety of a-tocopherol also 
interacts with the double bonds of unsaturated lipids. This interaction between a-
tocopherol and unsaturated phospholipids may render the lipids less susceptible to 
radical-induced injury (71,101,218,327). 
In a-tocopherol deficient animals, sarcolemmal membranes were abnormally 
permeable (215,240). The addition of a-tocopherol to liposomes decreased 
permeability to glucose and chromate ion (216). Philipson and Ward (259) reported 
enhanced permeability of cardiac sarcolemmal vesicles to calcium as the content of 
unsaturated fatty acids within the vesicles increased. Tocopherol-lipid interactions 
reduced the permeability of biological membranes containing relatively high levels of 
polyunsaturated fatty acids (70, 71). To assess the interaction of a-tocopherol, lipids 
and proteins within biological membranes, glucose transport was measured as a-
tocopherol was added to the culture media of mouse fibroblasts ( 105). In this tissue 
culture system, the addition of a-tocopherol increased fibroblast glucose uptake. 
Since the transport of glucose into cells is a carrier-mediated process, Giasuddin and 
Diplock (105) suggested that the integrity and maximal function of the plasma 
membrane was dependent on a structural interaction of a-tocopherol and other 
membrane components. 
Some authors suggest a metabolic role for vitamin E. Fedelesova et al. (85) 
reported decreased high energy phosphate stores in hearts from vitamin E deficient 
rats. Lactate dehydrogenase and malate dehydrogenase activities were decreased while 
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sarcolemmal sodium-potassium A TPase and sarcoplasmic reticular calcium A TPase 
activities increased. The increased sarcoplasmic reticular ATPase may ·be a 
compensatory mechanism for an increased intracellular calcium which has been 
reported with vitamin E deficiency. The ten week vitamin E deficient diet used by 
Fedelesova (85) depressed myocardial contractility even though there was no evidence 
of ultrastructural damage. These results may indicate that in the early stages of 
vitamin E deficiency myocardial energy production and utilization are altered. 
2. Glutathione Peroxidase 
Selenium-dependent glutathione peroxidase is another major defense against 
oxidizing agents and lipid peroxidation (150,212,328). It is found in plasma, the 
cytosol and the mitochondrial matrix (58). The enzyme is a tetramer with four 
identical subunits each containing one selenium atom (150,246,330). Selenium or 
more specifically a selenocystine moiety has been identified as the catalytic site for 
glutathione peroxidase (278,279,326). 
Glutathione peroxidase protects cellular and subcellular membranes from 
peroxidative damage. Using glutathione as a hydrogen donor (50), glutathione 
peroxidase catalyzes the reduction of hydrogen peroxide to water (212) thereby 
preventing the initiation of peroxidation (278,330). This enzyme also detoxifies 
membranes of fatty acid hydroperoxides preventing these peroxides from altering 
membrane structure and function (126). Working with phospholipase A2, glutathione 
peroxidase reduces polyunsaturated lipid hydroperoxides to hydroxy acids in the 
hydrophilic region of a membrane (212,279,290,327,330). Phospholipase A2 
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hydrolyses peroxidized fatty acids of membrane phospholipids (343). After release 
from the phospholipid, peroxidized fatty acids are available for reduction by 
glutathione peroxidase (36,58,325,330). It is estimated that 50 to 250 fatty acid 
hydroperoxides may be destroyed by one selenocystine moiety (360). In addition to 
destroying peroxides, glutathione peroxidase reduces secondary lipid peroxidation 
occurring with the breakdown of lipid hydroperoxides (360). 
Glutathione peroxidase activity increases with lipid peroxidation (330). If 
present in sufficient quantities glutathione peroxidase removes lipid peroxides as they 
are formed, before the peroxides alter membrane structure. Selenium deficiency 
results in reduced glutathione peroxidase activity (3,364), an inability to metabolize 
hydroperoxides through glutathione-dependent pathways (361), and decreased 
protection against free radicals (361,364). Cardiac muscle appears to be very 
sensitive to selenium depletion (46,150). Upon exposure to low dose oxygen radicals, 
decrease in function of isolated selenium-deficient rat hearts was significantly more 
pronounced than control hearts (364). 
Free radicals generated by catecholamine autoxidation may be involved in the 
development of catecholamine-induced cardiomyopathy (131,243,258,304). Singal et 
al. (304) have shown that vitamin E pretreatment prevented the deleterious effects of 
high dose ISO. These investigators (302) have also demonstrated increased 
lipoperoxidation in rat myocardium with ISO that was prevented by a-tocopherol 
pretreatment. Plasma from rats injected with 5 mg/kg EPI was cytotoxic to isolated 
cardiac myocytes after intracellular glutathione levels decreased (243). Since 
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ultrastructural changes did not occur until glutathione levels decreased, Noronha-Dutra 
et al. (243) proposed that free radicals were the cytotoxic agent which initiated _lipid 
peroxidation. The administration of selenium and vitamin E to pigs also afforded 
some protection to high dose ISO (344). The administration of selenium has also been 
shown to increase glutathione peroxidase activity and afford protection against lipid 
peroxidation (3, 46, 73, 126). 
This research indicates that adequate amounts of selenium-dependent 
glutathione peroxidase and a-tocopherol are essential for normal membrane physiology 
particularly if tissues are exposed to substances which directly or indirectly promote 
lipid peroxidation (59,150). Therefore, in the third study of this dissertation, a-
tocopherol and selenium will be administered over a two week period to increase the 
antioxidant capacity of the heart and determine if this pretreatment protected the rabbit 
myocardium from NE-induced injury. 
H. NO-REFLOW PHENOMENON 
No-reflow phenomenon is the failure to achieve uniform reperfusion following 
temporary ischemia (183) and has been described in various organs of a number of 
experimental animals. In 1966, Krug et al. (190) reported that significant portions of 
the endocardium could not be reperfused after temporary occlusions of 60-120 minutes 
in the cat. But it was not until 1974 that Kloner et al. (184) provided the first direct 
evidence that the no-reflow phenomenon occurred in the heart. The pathological 
mechanism causing the no-reflow phenomenon has not been elucidated however 
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several mechanisms including endothelial and myocyte swelling, ischemic contracture 
and rigor mortis, have been suggested (103). 
Brown and Egginton (31) demonstrated a loss of alkaline phosphatase staining 
in regions of ischemic injury in the heart. The loss of alkaline phosphatase, an 
enzyme normally present in capillary endothelium, indicated endothelial damage. 
Electron microscopic examination revealed no loss of capillaries 48 hours after NE 
infusion in the rabbit but capillary morphology was disrupted and endothelial cells 
were edematous. In areas of no-reflow present in the canine myocardium after 90 
minutes of ischemia, Kl oner demonstrated endothelial bleb formation, endothelial 
gaps, red blood cell aggregates and occasional thrombi within capillaries (184). 
Subsequently it was proposed that endothelial injury had prevented homogeneous 
reperfusion of the ischemic myocardium (183,184). However, the demonstration that 
colloidal thorium dioxide could pass through vessels with severely swollen 
endothelium showed vascular injury itself could not account for the no-reflow 
phenomenon. 
Compressive stress on the coronary microcirculation during ischemic 
contracture may contribute to the development of no-reflow (211). Ischemic 
contracture in isolated rat hearts has been associated with reduced flow in the 
subendocardium (104,211). Gavin et al. (104) showed that rat hearts subjected to 60 
minute global ischemia had no morphological evidence of endothelial swelling or 
constriction of any particular population of vessels and hypothesized that the 
endocardium of the left ventricle lost its ability to be reperfused because of 
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extravascular compression. Ischemic contracture closed subendocardial vessels and 
focal rigor mortis prevented vessels from opening with reperfusion (103). Vascular 
obstruction was not the essential cause of no-reflow. 
During prolonged catecholamine infusion, a-receptor mediated coronary 
vasoconstriction decreases and redistributes myocardial blood flow (135,301). 
Currently it is unknown if normal blood flow is reestablished to the ischemic areas 
after catecholamine infusion is terminated. In this dissertation, coronary blood flow 
was measured in rabbits after 40 minutes of NE infusion and at one hour post infusion 
to determine if the no-reflow phenomenon occurs with catecholamine-induced injury. 
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CHAPTER III 
GENERAL METHODS 
A. NOREPINEPHRINE-INDUCED CARDIOMYOPA THY 
Male, New Zealand white rabbits weighing approximately 2 kg were 
anesthetized with sodium pentobarbital (30 mg/kg IV). 0.9% sterile saline or 
norepinephrine bitartrate (NE; 2, 4, or 6 µg/kg/min) in 0.9% sterile saline was 
infused as a constant rate of 0.238 ml/min (Harvard Apparatus infusion/withdrawal 
pump, model 906) for 90 minutes via a 25-gauge needle inserted into the marginal ear 
vein. In rabbits used for acute experiments, the femoral artery was cannulated for 
monitoring arterial pressure. A standard Lead II ECG was recorded. Hearts were 
removed at the end of the infusion period for functional studies or 1 hour post-infusion 
for blood flow measurements. Rabbits used in chronic experiments did not have the 
femoral artery cannulated and were allowed to recover from the anesthetic. 
B. ISOLATED, NON-FJECTING HEART PREPARATION 
1. Langendorff Perfusion Apparatus 
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A non-recirculating I..angendorff apparatus with dual reservoirs and constant 
flow system was used in all isolated heart preparations (Figure 3-1). Heart~ were 
perfused with Krebs-Henseleit buffer (KHB; 118 mM NaCl, 4.8 mM KCl, 2.5 mM 
CaC12, 1.2 mM MgSO4 , 24 mM NaHCO3, and 1.2 mM KH2PO4) modified with the 
addition of 11 mM glucose, gassed with 95% 0 2 and 5% CO2 (pH=7.40 ± .03). 
Solutions were filtered through a 4 7 µm inline filter and warmed by Graham 
condensers and constant temperature circulator (Model 1267-00; Cole-Parmer 
Instrument Co.) to maintain intraventricular temperature at 37 ± 0.5°C. A series of 
valves following the condensers permitted rapid switching between reservoirs. A 
Masterflex peristaltic pump (Cole-Parmer Instrument Co.) regulated coronary flow at 
10 ml/min/g heart, wet weight (7). Although oxygen uptake was not measured, 
functional data indicated that this flow rate adequately perfused the isolated rabbit 
heart. Hearts increased ventricular function in response to increasing concentrations 
of NE and showed no signs of failure. Increasing coronary flow to 15 ml/min/g did 
not change perfusion pressure or ventricular function. However when flow was 15 
ml/min/g significant edema was apparent within 60 minutes. A sideport positioned 
after the pump permitted the addition of adrenergic agonists to the perfusate. 
Perfusion pressure was measured by a Gould Statham pressure transducer located near 
the aortic cannula and was recorded continuously on a Gould 2400S chart recorder. 
A bubble trap was positioned before a stainless steel aortic cannula. 
FIGURE 3-1 
LANGENDORFF PERFUSION APPARATUS 
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Schematic diagram of the non-recirculating, constant flow Langendorff 
perfusion apparatus used in ventricular function studies. 
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The pulmonary artery was cannulated with a 10 cm length of plastic tubing. 
A thermistor probe (Model 43 TA; Yellow Springs Instrument Co., Inc.) was· fed 
through this cannula, inserted into the right ventricular cavity and secured in place. 
Intraventricular temperature was monitored continuously. 
A balloon tipped cannula was used to measure relative left ventricular pressure 
(LVP). The compliant, fluid-filled (50% saline/50% ethanol; v:v) latex balloon was 
inserted into the left ventricle and connected to a Gould Statham pressure transducer 
via a 9 cm PE-190 cannula. A Hamilton syringe mounted next to the pressure 
transducer and connected via a three way valve to the balloon cannula permitted serial 
inflation of the intraventricular balloon and measurable changes in preload. The 
frequency response characteristics were calculated from the transient oscillations 
occurring after a step change in pressure (5). The balloon tipped cannula had a 
natural frequency of 301 ± 22.5 Hz and a damping coefficient of 0.49 ± .02. 
Although slightly underdamped, this system had a constant output/input amplitude 
ratio for frequencies up to 20% of the natural frequency (3). With hearts paced at 
220 beats/minute, the fundamental frequency of pressure generation was 3.7 Hz. 
Since the essential physiologic information was contained within frequencies up to 37 
Hz (12.3% of the natural frequency), this system was adequate to measure ventricular 
pressure and LV dP/dt. The transducer, cannula and balloon were checked daily for 
leaks and air bubbles. The balloon was stored in a small vial of 50 % saline/ 50 % 
ethanol (v:v) and thoroughly rinsed with KHB before use. Left ventricular dP/dt was 
derived from the LVP signal using a Gould Differentiator Amplifier (Model 13-4615-
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71). LVP and LV dP/dt were continuously recorded on a Gould 2400S chart 
recorder. 
KHB, KHB plus 10-6 M phentolamine (Regitine HCl, Ciba) or KHB plus 10-6 
M timolol (Timolol maleate; Merck) was stored in a reservoir of the Langendorff 
setup. Three-way valves below the Graham condensers allowed rapid switching 
between these perfusates. Norepinephrine, methoxamine, dobutamine and 
isoproterenol were infused via the sideport. Infusion rate was 2 ml/min. The amount 
of drug infused per minute was adjusted so the final concentration reaching the heart 
was that concentration stated in the methods. The bubble trap, containing 
approximately 10 ml solution, allowed for adequate mixing of the drug with the 
perfusate. 
2. Heart Isolation and Instrumentation 
After sodium pentobarbital anesthesia (30 mg/kg), 500 IU/kg sodium heparin 
was administered via the marginal ear vein. The abdomen was opened and the 
diaphragm cut off the rib cage. The thoracic cavity was opened with two axial 
incisions, from the diaphragm to the first or second rib. The anterior thoracic wall 
was lifted over the rabbit's head. The heart was excised quickly and placed in cold 
heparinized KHB. This procedure required 20 to 30 seconds from initial incision to 
immersion of the heart in cold KHB. All extraneous fat and connective tissue were 
removed from the aorta. The heart was weighed on a Mettler PL200 balance. Each 
heart was removed from the cold KHB, placed on a tared weighing boat, weighed and 
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quickly returned to the KHB. The weight of KHB remaining in the boat was 
subtracted from the heart weight. 
The aorta was cannulated and immediately perfused with warmed KHB. The 
left atrium was opened and a balloon tipped cannula was inserted into the left ventricle 
through the mitral orifice and secured. Care was taken so the balloon cannula was 
not forced against the ventricular wall or through the ventricular septum. The fluid 
within the balloon contained a drop of Evans Blue so bulging of the balloon into the 
left atria upon inflation was identified easily and balloon position corrected before 
beginning an experimental protocol. Balloon volume was adjusted to left ventricular 
end-diastolic pressure (L VEDP) of 5 mmHg. To prevent KHB accumulation within 
the left ventricular chamber a small cannula was inserted through the apical wall. A 
bipolar electrode attached to the right atrial appendage was used to pace hearts at 220 
beats/min. 
After instrumentation, hearts were perfused for an additional 20 minutes before 
experiments were begun. During this time contractions become regular and 
intraventricular pressure fluctuations reach steady state. Only hearts meeting the 
following criteria were used in this study: 1) baseline peak systolic pressure greater 
than 80 mmHg (EDP = 5 mmHg) in hearts from rabbits infused with saline and ~ 
65 mmHg in hearts from rabbits treated with NE; 2) stable coronary perfusion 
pressure; and 3) heart following pace of 220 beats/minute. 
C. MEASUREMENT OF DIASTOLIC FUNCTION 
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Two parameters of diastolic function, LV -dP/dlmax and tau, were evaluated in 
cardiac function experiments. Tau, the time constant for isovolumic relaxation, was 
measured from the L VP trace after the experiment. Isovolumic relaxation is delimited 
by the closure of the aortic valve and opening of the mitral valve. Negative L V 
dP/dlmax has been reported to be the best indicator of aortic valve closure (1). 
Therefore, tau has been defined as the time required for LV cavity pressure at -dP/dt 
to be reduced by a factor of 1/e (6). Normally LV -dP/dlmax occurs before peak 
systolic pressure has decreased by 40.0% (1,4,8). Using the balloon tipped cannula 
system in the isolated heart, LV -dP/dlmax did not occur until peak systolic pressure 
decreased by 63 % . This point, being extremely low on the L VP trace, did not 
accurately represent the beginning of isovolumic relaxation. In these experiments a 
constant of 75 % peak systolic pressure was designated as the beginning of isovolumic 
relaxation. Accordingly, tau was defined as the time required for ventricular pressure 
at 75 % peak systolic pressure to be reduced by 1/e. Tau was measured at 5 mmHg 
LVEDP. 
D. EXPERIMENT AL PROTOCOLS FOR ISOLA TED HEART PREPARATION 
1. Ventricular Function and {3-Adrenoceptor Mediated Inotropy 
These studies were designed to assess acute and chronic alterations in L V 
function with NE-induced injury. In acute studies, L V performance was assessed 
immediately after saline or NE infusion. Chronic experiments were performed 48 
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hours after the infusion. To eliminate neural and hormonal influences, the isolated 
perfused heart preparation was used in all functional studies. 
With hearts paced at 220 beats/minute, baseline L V function was measured as 
LVEDP was increased from Oto 25 mmHg (5 mmHg steps). Steady state LVP and 
LV dP/dlmax were recorded at each EDP. Hearts were perfused with incremental, 
cumulative concentrations of NE, 10-10 to 10-7 M. At each concentration, LVEDP was 
increased from Oto 25 mmHg and steady state LVP and LV dP/dlmax were recorded. 
At the termination of each inflation series, the intraventricular balloon was deflated 
and L VEDP readjusted to 5 mmHg. Hearts were perfused with KHB until ventricular 
function returned to baseline. 
/3-Adrenoceptor mediated inotropy was assessed in the presence of a-
adrenergic blockade (10--6 M phentolamine). a-Receptor blockade was tested with 10-7 
M methoxamine then baseline ventricular function measurements were recorded. 
Hearts were perfused with increasing concentrations of dobutamine (10-9 - 10--6 M), a 
selective /31-agonist. LVEDP was varied from O to 25 mmHg at baseline and each 
dobutamine concentration. Steady state developed LVP and LV dP/dlmax were 
recorded. 
2. a-Adrenoceptor Mediated Changes in Ventricular Function 
The inotropic response to a-adrenergic stimulation was measured m the 
isolated heart immediately after NE (4 µg/kg/min) infusion and 48 hours post saline 
or NE infusion. Isolated heart was paced at 220 beats/minute and LVEDP was 
maintained at 5 mmHg. Baseline ventricular function was recorded then each heart 
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was perfused with cumulative, decreasing concentrations of NE (10"6 - 10-7 M). The 
heart was washed for 20 minutes with KHB and L V function returned to baseline 
values. Timolol (10-6 M), a nonselective t3-adrenergic antagonist, was added to the 
perfusate. After ten minutes, t3-receptor blockade was tested with 10-7 M 
isoproterenol. Hearts were re-exposed to the incremental decreasing concentrations 
of NE (10-6 - 10-7 M). LVP and LV dP/dlmax were recorded at baseline, in the 
presence of timolol and after two minutes at each NE concentration. Changes in L V 
function attributed to NE stimulation of a-adrenergic receptor were determined. 
3. a-Tocopherol and Selenium Administration 
Thirteen male, New Zealand white rabbits (2.2 kg) were treated 
subcutaneously with a-tocopherol (25.0 mg; BO-SE, Schering Co., U.S.A.) and 
selenium (0.5 mg) every other day for two weeks. Twenty-four hours after the last 
treatment rabbits were anesthetized with intravenous sodium pentobarbital (30 mg/kg). 
Saline (n=6) or 4 µg/kg/min NE (n=7) was infused for 90 minutes via the marginal 
ear vein. Infusion rate was constant at 0.238 ml/min. Ventricular function was 
studied two days post infusion using the isolated heart preparation. 
Baseline LV function was measured as LVEDP was increased from Oto 25 
mmHg in 5 mmHg steps. Hearts were perfused with incremental, cumulative 
concentrations of NE (lQ-9 - 10"6 M). At each concentration of NE, LVEDP was 
increased from Oto 25 mmHg and steady state developed LVP and LV dP/dlmax were 
recorded. LVEDP was readjusted to 5 mmHg following each serial increase in EDP. 
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E. MYOCARDIAL BLOOD FLOW 
This study was designed to determine if rabbit heart exhibited the no-reflow 
phenomena after a 40 minute NE infusion. Blood flow measurements were made at 
O and 40 minutes of the NE (4 µg/kg/min) or saline infusion and at one hour post-
infusion. In another group of rabbits myocardial blood flow was measured 48 hours 
after NE infusion. 
1. Surgical Preparation 
Male, New Zealand white rabbits were anesthetized with sodium pentobarbital 
(30 mg/kg IV). The trachea was cannulated with a glass Y-tube connected to a 
Harvard Apparatus respirator (Model 661). Each rabbit was ventilated with room air 
at an end-expiratory pressure of 1 cm of water. Lead II ECG was measured with 
needle electrodes. Body temperature was monitored and maintained at 38 + 1 °C with 
a heat exchanger and heating pad. The femoral arteries were cannulated with 
polyethylene catheters (PE-90). The right arterial cannula was connected to a Gould 
Statham pressure transducer for measurement of arterial blood pressure. The left 
arterial cannula was connected to a Harvard Apparatus infusion/withdrawal pump 
(Model 906) for the withdrawal of blood samples during microsphere injection. In 
acute experiments, a femoral vein was cannulated for the infusion of saline or NE. 
After a left thoracotomy, the left atrial appendage was cannulated with a short piece 
of PE-160 tubing. This cannula permitted atrial injection of microspheres. Arterial 
pressure and ECG were monitored throughout the experiment and recorded on a 
Gould chart recorder. 
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2. Blood Flow Determination 
The following species of radioisotope labeled microspheres (3M Co, New 
England Nuclear) were used: Ce-141, Nb-95, Sr-85, and Ru-103. These microspheres 
(14.5 ± 0.6 µm) were suspended in 10% dextran with 0.05% polyoxyethelene-20 
sorbitan mono-oleate (Tween 80) to deter the inherent microsphere aggregation. Vials 
containing the microspheres were sonicated for at least 20 minutes before use and 
were vigorously agitated in a vortex mixer immediately prior to injection. For each 
blood flow measurement approximately 1 x 1()6 microspheres were injected so a 
minimum of 400 spheres were trapped in each myocardial sample. Microspheres 
were injected through the atrial cannula over a 20-30 second period then the cannula 
was flushed with 0.5 ml warm saline. A reference blood sample was withdrawn from 
the femoral artery at a rate of 3-4 ml/min. Blood withdrawal began 30 seconds before 
the injection of microspheres and continued for 30-40 seconds post-injection. 
Withdrawal pump rate was calibrated at the end of each experiment. The reference 
blood sample was put into plastic counting tubes. The syringes which contained blood 
were rinsed and the rinse added to respective blood sample counting tubes. At the 
termination of the experiment, the heart was removed. The atria, right ventricular 
free wall and left ventricle were isolated and fixed for 24-48 hours in 10% formalin. 
The atria and right ventricular free wall were weighed and placed in counting tubes. 
The left ventricle was cut into 5-6 rings. Each ring was separated into endocardial 
and epicardial halves via a circumferential cut at a point midway between the 
epicardial and endocardial surfaces. Endocardial and epicardial samples were weighed 
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and placed in separate plastic counting tubes. The radioactivity of the heart and 
reference blood tissue samples were counted by a three inch Nal crystal within a TM 
Analytic gamma counter (Model 1185). Radioactivity counts were sent directly to a 
computer and stored on floppy disc for later analysis. 
Blood flow was calculated using the theoretical organ technique. Using 
radioactivity counts, calculated withdrawal rate of reference blood sample and tissue 
weights, a Compaq 286 computer calculated blood flow in ml/min/ 100 g tissue. 
Standard equations with appropriate corrections and interference coefficients were 
used. The following equation was used to calculate blood flow: MBF = (Ct/TW) x 
(RBW/Cb), where MBF = myocardial blood flow in ml/min/100 g, Ct = tissue 
radioactivity in counts/min, TW = weight of tissue sample in grams, RBW = 
reference blood withdrawal rate in ml/min, and Cb = total radioactivity in reference 
blood sample. 
F. HISTOLOGY 
After termination of several L V function experiments, hearts were removed 
from the perfusion apparatus and weighed. The atria and right ventricular free wall 
were dissected from the left ventricle. A midlevel transverse section of L V and 
septum was taken from each heart and placed in a plastic tissue capsule. Tissue was 
fixed in 10% buffered formalin solution and further processed with an Autotechnicon 
Mono Model 2A (Technicon Corporation) tissue processor. Tissue processing 
included 6 hour tissue alcohol dehydration, 3 hour xylene clearing and 2 hour 
94 
impregnation with paraffin. The processing cycle occurred over 12 hours and was 
followed by embedding in paraffin. Tissue specimens were cut in 10 µ sections (820 
Microtome, American Optical Spenser) and placed on microscope slides. Each slide 
was warmed slightly so the section would adhere to the glass slide during the staining 
procedure. After a series of xylene and alcohol washes, tissue sections were stained 
with hematoxylin and eosin (2). Staining was followed by another series of alcohol 
and xylene washes. The microscope slides were dried and the coverslips permanently 
mounted. LV sections were viewed to verify the presence or absence of myocardial 
injury. This injury was noted by edema, loss of nuclei, focal myofibrillar destruction, 
and the presence of cellular infiltration. 
G. DATA ANALYSIS 
All data was expressed as mean ± SEM. Analysis of variance (ANOV A) with 
repeated measures was used to test for differences over time in heart rate and blood 
pressure during saline or NE infusion. A two way ANOV A was used to test for 
differences between groups at each time point or drug concentration. The Student-
Newman Keuls test was used to isolate differences. In the myocardial blood flow 
studies, an ANOV A with repeated measures was used to test for changes in heart rate, 
mean arterial pressure, rate-pressure product, blood flow and vascular resistance 
during and after NE or saline infusion. At-test with a Bonferroni correction was used 
to isolate differences. A two way ANOV A was used to test for differences between 
groups. Values of p < 0.05 was considered statistically significant. Glantz Primer 
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of Biostatistics Program or SAS (Statistical Analysis System) was used for all 
statistical tests. 
96 
H. REFERENCES 
1. ABEL, F.L. Maximal negative dP/dt as an indicator of end systole. Am. J. 
Physiol. 240:H676-H679, 1981. 
2. ARMED FORCES INSTITUTE OF PATHOLOGY Manual of histological and 
special staining technics. New York:Blakeston Division, McGraw-Hill Book Co., 
1960, 
3. FRY, D.L. Physiological recording by modern instruments with particular 
reference to pressure recordings. Physiol. Rev. 40:754-788, 1960. 
4. GAASCH, W.H., M.R. ZILE, A.S. BLAUSTEIN, and O.H.L. BING. Loading 
conditions and left ventricular relaxation. In: Diastolic Relaxation of the Hean, 
edited by GROSSMAN, W., and B.H. LORELL. Boston:Martinus Nijhoff 
Publishing, 1988, p. 133-142. 
5. GROSSMAN, W. Pressure Measurement. In: Cardiac Catherization and 
Angiography,( 3rd ed.), edited by GROSSMAN, W. Philadelphia:Lea and 
Febiger, 1986, p. 118-134. 
6. MIRSKY, I. Assessment of diastolic function: suggested methods and future 
considerations. Circulation 69:836-841, 1984. 
7. VOGEL, W.M., C.S. APSTEIN, L.L. BRIGGS, W.H. GAASCH, and J. AHN. 
Acute alterations in left ventricular diastolic chamber stiffness: Role of the 
"erectile" effect of coronary arterial pressure and flow in normal and damaged 
hearts. Circ. Res. 51:465-478, 1982. 
8. WEISFELDT, M.L., H.B. SCULLY, J. FREDERIKSEN, J.J. RUBENSTEIN, 
G.M. POHOST, E. BEIERHOLM, A.G. BELLO, and W.M. DAGGETT. 
Hemodynamic determinants of maximal negative dP/dt and periods of diastole. 
Am. J. Physiol. 277:613-621, 1974. 
CHAPTER IV 
VENTRICULAR DYSFUNCTION IN 
NOREPINEPHRINE-INDUCED CARDIOMYOPA THY 
A. INTRODUCTION 
Myocardial lesions produced by excessive administration (19,23,26) or release 
of catecholamines from the sympathetic nervous system (7, 14,21) have been well 
characterized. Typical lesions including myofibrillar degeneration, leukocyte 
infiltration and focal necrosis (10, 13, 16,20,25) can be induced by a variety of 
catecholamines (3 ,9, 13) including norepinephrine (NE)(5 ,23 ,24 ,26). The severity and 
extent of myocardial injury is dependent on the dose and rate of catecholamine 
administration (13,22). 
cardiomyopathy (8,21,22). 
Resultant injury has been termed catecholamine 
Cardiac dysfunction also follows prolonged exposure to high circulating levels 
of catecholamines. Left ventricular systolic function is depressed (2, 16) and 
responsiveness to NE is attenuated (16) in vivo two days post NE infusion. Diastolic 
function, however has not been systematically evaluated. In addition, the time course 
of ventricular dysfunction has not been fully investigated. The isolated non-ejecting 
heart preparation was used to eliminate neural and endocrine factors. 
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Thus, the purpose of this study was threefold: (1) to evaluate ventricular 
systolic and diastolic function in hearts from rabbits infused with 2, 4, or 6 µg/kg/.min 
NE for 90 minutes, (2) to determine if cardiac performance is impaired immediately 
after prolonged exposure to high catecholamines and (3) to determine if ventricular 
function has changed by two days post NE infusion. 
B. METHODS 
1. Norepinephrine-induced Cardiomyopathy 
Forty-nine male, New Zealand white rabbits (1.5 - 2.3 kg) were anesthetized 
with intravenous sodium pentobarbital (30 mg/kg). A modification of Downing and 
Lee's model of norepinephrine-induced cardiomyopathy (8) was used in this study. 
Saline or norepinephrine bitartrate (NE) in saline was infused for 90 minutes via the 
marginal ear vein. Infusion rate was constant at 0.238 ml/min. Ventricular function 
was studied in twenty-six hearts isolated immediately after the infusion period and in 
twenty-three hearts two days post infusion. For acute experiments, rabbits were 
infused with saline (n=6; SAL-A), 2 µg/kg/min NE (n=8; NE2-A), 4 µg/kg/min NE 
(n=6; NE4-A) or 6 µglkglmin NE (n=6; NE6-A). A standard Lead II ECG and 
arterial pressure were monitored throughout the infusion period. For chronic 
experiments, rabbits were infused with saline (n=5; SAL-C), 2 µg/kg/min NE (n=6; 
NE2-C), 4 µg/kg/min NE (n=6; NE4-C) or 6 µg/kg/min NE (n=6; NE6-C). Rabbits 
used in chronic experiments were allowed to recover from the anesthetic. 
2. Isolated Heart Preparation 
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Following administration of sodium pentobarbital (30 mg/kg, IV), heparin (500 
JU/kg) was administered via the marginal ear vein. The thoracic cavity was opened 
and the heart was quickly excised and placed in cold heparinized Krebs-Henseleit 
buffer modified with 11 mM glucose (KHB; pH 7.4). The aorta was cleaned of fat 
and connective tissue and the heart was weighed. The heart was placed on a non-
recirculating, constant flow Langendorff apparatus. Each heart was perfused with 
KHB at 10 ml/min/g wet weight. The solution was warmed by Graham condensers 
and constant temperature circulator to maintain intraventricular temperature at 37 ± 
0.5°C. A right atrial bipolar electrode was used to pace hearts at 220 beats/min. The 
pulmonary artery was cannulated to hinder flow of effluent into the left ventricle. A 
small cannula was inserted through the apex of the left ventricle to prevent fluid 
accumulation within the chamber. To measure left ventricular pressure (LVP), a 
fluid-filled latex balloon was inserted into the left ventricle through the mitral valve 
orifice. The balloon was connected to a Statham pressure transducer with a 9 cm 
length of polyethylene tubing. A Hamilton syringe positioned between the balloon and 
pressure transducer allowed for changes in balloon volume. After securing the 
balloon in the L V, balloon volume was adjusted so L V end-diastolic pressure 
(LVEDP) was 5 mmHg. 
3. Protocol 
After a 30 minute equilibration period, LVEDP was varied from 0 to 25 
mmHg (5 mmHg steps) then reset to 5 mmHg. Control LVP, LV +dP/dt:.nax and LV 
-dP/dt:.nax were recorded at each LVEDP. Hearts were exposed to cumulative, 
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increasing concentrations of NE (l0-10 - 10-7 M). At each NE concentration, LVEDP 
was varied from Oto 25 mmHg (5 mmHg increments) then reset to 5 mmHg. Steady 
state LVP, LV +dP/d½nax and LV -dP/d½nax were recorded. 
4. Data analysis 
All values are expressed as mean ± SEM. Analysis of variance (ANOVA) 
with repeated measures was used to test for differences in heart rate or blood pressure 
within each group over the 90 minute saline or NE infusion. A two way ANOV A 
was used to test for differences between groups. The Student-Newman Keuls test was 
used to isolate differences. Values of p < 0.05 were considered statistically 
significant. 
C. RESULTS 
Heart rates immediately prior to saline (281 ± 7.3 beats/min) or NE infusion 
at 2 µg/kg/min (291.7 ± 3.1 beats/min), 4 µg/kg/min (281.7 ± 8.6 beats/min) or 6 
µg/kg/min (293 + 3.0 beats/min) were not different. Over the 90 minute infusion 
period, heart rates decreased slightly (10-20 beats/min), though insignificantly, in all 
groups. Mean arterial pressure (Figure 4-1) increased 25 to 35 mmHg above baseline 
within two minutes of NE infusion (all doses) and remained elevated significantly 
during the entire infusion period. Arterial pressure did not change during saline 
infusion. 
Baseline ventricular function is summarized in Tables 4-1 and 4-2. There was 
no difference between SAL-A and SAL-C in any measure of ventricular function so 
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these groups were combined (SAL). At the end of the infusion period, LVP 
developed by NE2-A, NE4-A, and NE6-A was less than SAL (Figure 4-2, panel A). 
The peak L VP developed in the NE treated groups was inversely related to the infused 
dose of NE. However, peak L VP was not significantly different between groups 
except at LVEDP of 0 and 5 mmHg. At these LVEDP's, NE6-A peak LVP was 
significantly lower than SAL, 76.0 ± 6.6 vs 99.4 ± 3.7 mmHg at EDP = 0 mmHg 
and 90.3 ± 4.7 vs 105.8 ± 3.8 at EDP = 5 mmHg. Two days post infusion, the 
peak L VP developed by NE6-C was depressed compared to SAL, NE2-C and NE4-C 
(Figure 4-2, panel B). NE2 and NE4 were not different from SAL. As demonstrated 
in figure 4-2, changes in LVP with increasing LVEDP (0-25 mmHg) were similar in 
NE treated hearts and SAL acutely and at 48 hours post infusion. 
Immediately after infusion, LV +dP/dlmax and LV -dP/dt.n..x were depressed 
(LVEDP 0-25 mmHg) significantly in NE2-A, NE4-A, and NE6-A as compared to 
SAL (Table 4-1, Figure 4-4, panel A and Figure 4-5, panel A). At 48 hours, LV 
+dP/dlmax of all NE injured hearts remained lower than SAL at each LVEDP but only 
NE6-C LV +dP/dlmax was significantly less than SAL (Table 4-2 and Figure 4-4, 
panel B). Negative LV dP/dlmax also was depressed significantly at all LVEDP's in 
NE2-C, NE4-C, and NE6-C (Table 4-2). At LVEDP of 5 mmHg (Figure 4-5, panel 
B), LV -dP/dlmax was -1235.7 ±32.2 mmHg/sec for SAL, compared to -1066.9 ± 
72.3, -1028.7 ± 333.7 and -926.3 ± 58.8 mmHg/sec for NE2-C, NE4-C and NE6-
C, respectively. 
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FIGURE 4-1 
CHANGE IN MEAN ARTERIAL PRESSURE DURING 
SALINE OR NOREPINEPHRINE INFUSION 
o-o SAL 
w 1-_r •-• NE2 A-A N£4 
11{(1 -~ •-• N£6 • ... __ r r 
'l '• e. •~ A 
111"----.--i -==::!~ 
1 t 
. ------0 'oo or_b-o 'o 0 
B 10 20 30 60 
Inf us ion Time (min) 
102 
f -. 
1 
X 
90 
Mean ± SEM for changes from baseline (B) in mean arterial pressure (MAP) 
during 90 minute infusion of saline (SAL) or norepinephrine at 2 (NE2), 4 (NE4), and 
6 (NE6) µg/kg/min. Norepinephrine (all concentrations) significantly increased MAP 
above baseline (p < 0.05). MAP was elevated significantly during NE infusion 
compared to SAL. 
TABLE 4-1 
BASELINE VENTRICULAR FUNCTION IMMEDIATELY FOLLOWING 
HIGH DOSE NOREPINEPHRINE INFUSION 
L VEDP (mmHg) 0 
Peak LVP (mmHg) 
SAL 
NE2 
NE4 
NE6 
99.4 ± 3.7 
87.6 ± 5.7 
83.3 ± 5.6 
76.0 ± 6.6* 
LV +dP/dt (mmHg/sec) 
SAL 
NE2 
NE4 
NE6 
1762.0 + 74.8 
1400.3 + 135.4* 
1293.3 ± 66.8* 
1205.2 ± 122.7* 
LV -dP/dt (mmHg/sec) 
SAL 
NE2 
NE4 
NE6 
-1272.5 + 39.3 
-962.0 + 58.9* 
-925.1 + 45.9* 
-922.8 + 87.1 * 
10 
114.6 ± 3.3 
107.4 ± 4.3 
97.8 ± 5.3 
97.0 ± 9.0 
1809.9 ± 85.6 
1567.9 ± 119.5 
1367.4 ± 58.9* 
1390.9 ± 158.2* 
-1279.2 + 38.7 
-1028.3 ± 57.6* 
-929.5 ± 39.1 * 
-986.4 + 81.6* 
20 
126.8 ± 3.3 
115.3 ± 4.0 
109.7 ± 5.7 
109.7 ± 7.8 
1885.3 ± 84.1 
1535.2 ± 119.8* 
1400.6 ± 67.8* 
1429.0 ± 144.0* 
-1273.9 ± 38.6 
-980.2 ± 55.0* 
-925.0 ± 35.1 * 
-944.9 ± 63. 7* 
Hearts from rabbits infused with saline (SAL) or norepinephrine at 2 (NE2), 4 (NE4), and 6 (NE6) µg/kg/min for 90 
min. LVP, left ventricular pressure; dP/dt, first derivative of LVP. Values are rnean ± SEM. * Significantly 
different from SAL (p < 0.05). -0 
v) 
TABLE 4-2 
BASELINE VENTRICULAR FUNCTION 48 HOURS AFTER EXPOSURE TO 
HIGH DOSE NOREPINEPHRINE 
LVEDP (mmHg) 0 
Peak L VP (mmHg) 
SAL 
NE2 
NE4 
NE6 
99.4 ± 3.7 
90.7 ± 4.9 
101.5 ± 3.3 
82.3 + 6.0*t 
LV +dP/dt (mmHg/sec) 
SAL 
NE2 
NE4 
NE6 
1762.0 ± 74.8 
1393.5 ± 116.7* 
1624.2 + 69.8 
1304.6 ± 66.1 * 
LV -dP/dt (mmHg/sec) 
SAL -1272.5 ± 39.3 
NE2 -986.4 ± 75.1 * 
NE4 -1047.2 ± 35.5* 
NE6 -952.1 ± 48.4* 
10 
114.6 ± 3.3 
113.5 ± 2.0 
111.9±3.6 
95.3 ± 5.3 *t:j: 
1809.9 ± 85.6 
1589.3 ± 105.6 
1650.2 ± 79.6 
1348.9 ± 43.1 * 
-1279.2 ± 38.7 
-1085.2 + 68.3* 
-1008.3 ± 36.4* 
-910.7 ± 39.7* 
20 
126.8 ± 3.3 
126.1 ± 5.1 
120.9 ± 3.0 
105.3 ± 5.5*t:j: 
1885.3 ± 84.1 
1731. 7 ± 199 .1 
1679.4 ± 55.2 
1361.6 ± 48.5* 
-1273.9 ± 38.6 
-1046.9 ± 90.3* 
-960.1 ± 21.7* 
-877.4 ± 10.6* 
Values are mean ± SEM. Abbreviations as in table 4-1. * Significantly different from SAL (p < 0.05), t 
Significantly different from NE2, + Significantly different from NE4. 
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FIGURE 4-2 
PRESSURE FUNCTION CURVES FOR NORMAL AND 
CARDIOMYOPATHIC HEARTS 
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A 
B 
Pressure function curves generated hearts from rabbits infused with saline 
(SAL) or norepinephrine at 2 (NE2), 4(NE4), and 6 (NE6) µg/kg/min for 90 min. 
Panel A: ventricular function assessed immediately following the infusion period. 
Panel B: ventricular function at 48 hours post infusion. Data presented as mean ± 
SEM. * Significantly different from SAL (p < 0.05), # Significantly different from 
NE2, 0 Significantly different from NE4. 
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FIGURE 4-3 
NOREPINEPHRINE LV PRESSURE DOSE-RESPONSE CURVES 
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NOREPINEPHRINE CONCENTRATION (M) 
Effect of norepinephrine on left ventricular pressure (L VP) development 
acutely (panel A) and at 48 hours (panel B) post infusion. End diastolic pressure is 
constant at 5 mmHg. Abbreviations as in Figure 4-2. * p < 0.05 compared to SAL, 
# p<0.05 compared to NE2, 0 p<0.05 compared to NE4. 
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FIGURE 4-4 
NOREPINEPHRINE LV +dP/dlmu DOSE-RESPONSE CURVES 
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NOREPINEPHRINE CONCENTRATION (M) 
Norepinephrine dose-response curve generated immediately post infusion (panel 
A) or at two days (panel B). End diastolic pressure is 5 mmHg. LV +dP/dt, first 
derivative of LVP; other abbreviations as in Figure 4-2. * Significantly different from 
SAL (p < 0.05). 
FIGURE 4-5 
NOREPINEPHRINE LV -dP/dt.n.x DOSE-RESPONSE CURVES 
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Effect of increasing concentrations of norepinephrine on maximal rate of 
pressure decline (LV -dP/dt) in hearts isolated immediately after (panel A) or two 
days post (panel B) saline or norepinephrine infusion. Diastolic pressure = 5 mmHg. 
Abbreviations as in Figure 4-2. * p < 0.05 compared 
to SAL. 
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LV systolic function, LVP and LV +dP/d1m..x, of NE2 and NE4 showed 
improvement within 48 hours after NE infusion. Peak LVP increased slightly in ·all 
NE treated groups, however, the increase (L VEDP of O and 5 mmHg) was significant 
only in NE4-C. Positive LV dP/df.nax also improved significantly in NE4, but not in 
NE2 and NE6. Diastolic function, as indicated by LV -dP/df.nax, did not recover 
within two days post NE treatment. 
Changes in cardiac function in response to increasing concentrations of NE are 
presented in Figures 4-3, 4-4 and 4-5. LVEDP shown in these figures is 5 mmHg 
and is representative of ventricular responses to NE at other diastolic pressures. In 
response to 10-7 M NE, LVP increased 37.0 ± 4.4, 24.6 ± 3.4, 33.2 ± 5.8 and 30.8 
± 7.9 mmHg above baseline in SAL, NE2-A, NE4-A, and NE6-A respectively. 
Increase in LVP with 10-7 M NE was similar in hearts studied two days post infusion. 
Although baseline function was depressed, myopathic hearts increased LV +dP/dt.n...x 
and LV -dP/d1m..x the same amount as SAL at 10·1 M NE. In addition, there was no 
difference in percent increase in LVP, LV +dP/df.nax and LV -dP/d1uiax of SAL, NE2, 
NE4, or NE6 in response to increasing concentration of NE in acute and chronic 
experiments. 
E. DISCUSSION 
Pressure function curves presented in our study for saline treated animals are 
consistent with those previously reported for the isolated, non-ejecting rabbit heart 
(15). We also show a downward shift of the function curve with NE injury acutely 
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with some functional improvement by 48 hours. Increases in L VP with changing 
LVEDP was similar in our SAL and NE groups. Using the open-chest rabbits, 
Werner and associates (27) reported in control animals very small increases in 
LVEDP with aortic constriction until LVP exceeds 150 mmHg. Hearts in rabbits 
treated with NE two days before assessment of L V function showed greater increases 
in LVEDP for a given change in L VP. The apparent difference between results 
published by Werner, et al. (27) and those reported here may be an inherent property 
of differences in the experimental models. Pressure function curves are afterload 
dependent. Afterload in the isolated, non-ejecting heart preparation is infinite whereas 
it is measurable in the whole animal. The conclusion however is the same. 
Ventricular function as measured by pressure function curves is depressed with NE-
induced injury. In addition, cardiac output index, minute work index (2) and the 
ability to perform stroke work (4) are attenuated in catecholamine cardiomyopathy. 
Cardiac function studies in vivo showed no difference in resting LV +dP/d~ 
two days post NE infusion between control and NE-treated rabbits (2, 12). The result 
of the present series of experiments are consistent with this data. Positive LV dP/d~ 
is depressed acutely with infusion of 2, 4, or 6 µg/kg/min NE. Two days post 
infusion NE2 and NE4 have returned toward control. However, systolic dysfunction 
(LV +dP/d~J does not improve within 48 hours after exposure to very high 
concentrations of NE (6 µg/kg/min). Prolonged NE infusion may have acutely 
depressed cross-bridge formation or actin-myosin ATPase activity resulting in 
decreased systolic function. Additionally, a greater number of cardiac myocytes may 
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have been permanently damaged by the 6 µg/kg/min NE infusion thereby hindering 
the recovery of systolic function by 48 hours post infusion. 
In contrast to our results, Lee and Downing (12, 16) have reported a decreased 
ability to improve myocardial contractility in rabbits two days after NE infusion (2 
µg/kg/min for 90 min). In their studies (12, 16), myopathic hearts in vivo did not 
increase LV +dP/dt.n.x the same percent as control in response to increasing 
concentrations of NE. In the isolated heart preparation used in the current study, NE 
injured hearts increased LVP, LV +dP/dluuu, and LV -dP/dluux the same amount as 
SAL both acutely and at two days. It may be that extra-cardiac factors influenced L V 
response in situ. 
During the pathogenesis of catecholamine-induced cardiomyopathy, elevated 
circulating catecholamines augment the flux of calcium into myocardial cells 
(1, 11,22). Initially higher intracellular calcium levels are buffered by increased 
microsomal and mitochondrial transport (18). Later, microsomal calcium pump 
activity (18), sarcolemmal Na-Ca exchange and Ca pump activities (6, 17) become 
depressed. These changes in calcium transport coupled with functional deterioration 
of mitochondria (11) result in elevated intracellular calcium (11,22). Higher levels 
of intracellular calcium and impaired removal of calcium during diastole may 
contribute to the decreased rate of ventricular relaxation. Cellular degeneration and 
intracellular and extracellular edema increase myocardial stiffness and may also 
contribute to diastolic dysfunction. The diastolic injury in norepinephrine-induced 
cardiomyopathy was not transient. Diastolic function was not improved 48 hours after 
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injury although systolic function showed improvement in NE2 and NE4. The time 
course and degree of recovery of diastolic function in cardiomyopathic rabbits was ·not 
assessed beyond two days post injury. 
In summary, these experiments indicate that left ventricular diastolic function, 
in addition to systolic function is impaired acutely after exposure to high levels of 
catecholamines. Systolic function improved within 48 hours of injury whereas 
diastolic function remained depressed. 
113 
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CHAPTER V 
ADRENERGIC RECEPTOR MEDIATED CHANGES IN VENTRICULAR 
FUNCTION IN NOREPINEPHRINE-INDUCED CARDIOMYOPATHY 
A. INTRODUCTION 
Prolonged exposure to catecholamines reduces responsiveness to adrenergic 
receptor stimulation in many organ systems and cell lines (3,6, 13, 19,24). This 
desensitization may result from the uncoupling of receptors from their effector enzyme 
systems or the removal of receptors from the plasma membrane (13-15). Both 
desensitizing mechanisms have been demonstrated for cardiac ~-adrenergic receptors 
(11,12,16). In fact, uncoupling of rat cardiac ~-receptors and a decrease in ~-receptor 
density has been reported following prolonged norepinephrine (NE) infusion while 
cardiac acreceptors were not desensitized (5). 
Exposure of cardiac tissue to high concentrations of catecholamines may induce 
myocardial damage. Characteristic histological lesions include contraction bands, 
myofibrillar degeneration and focal necrosis (8,9,21). A defect in the cardiac ~-
adrenergic receptor-adenylate cyclase system has also been identified. The guanine 
nucleotide regulatory (G) protein and/or adenylate cyclase enzyme were altered by 
high dose catecholamines so direct stimulation of the G protein by NaF or Gpp(NH)p 
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elicited a reduced response of adenylate cyclase (7 ,22). 
If high levels of circulating catecholamines uncouple the ~-receptor from its 
G protein (13,14) or alter the function of the G protein or adenylate cyclase enzyme 
(7,22), ~-receptor mediated increases in ventricular function should be depressed. In 
this case, the a-adrenergic receptor system may be more important in increasing 
cardiac performance after catecholamine injury. The purpose of this study was (1) 
to evaluate a- and ~-adrenergic receptor mediated changes in left ventricular function 
immediately after a 90 minute norepinephrine infusion and at 2 days post infusion and 
(2) to determine if the a-receptor system has a greater role in increasing cardiac 
function after NE induced injury. 
B. METHODS 
1. Norepinephrine-Induced Cardiomyopathy 
NE cardiomyopathy was induced in sixty-six male, New Zealand white rabbits 
(1.5 - 2.3 kg). Following the administration of intravenous sodium pentobarbital (30 
mg/kg), saline or NE bitartrate in saline was infused for 90 minutes via the marginal 
ear vein. 
Ventricular responsiveness to ~i-adrenoceptor agonist dobutamine was studied 
in twenty-six hearts isolated immediately after the infusion period and in twenty-three 
hearts two days post infusion. For acute experiments, rabbits were infused with saline 
(n=6; SAL-A), 2 µg/kg/min NE (n=8; NE2-A), 4 µg/kg/min NE (n=5; NE4-A) or 
6 µg/kg/min NE (n=6; NE6-A). A standard Lead II ECG and arterial pressure were 
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monitored throughout the infusion period. In chronic experiments, rabbits were 
infused with saline (n=5; SAL-C), 2 µg/kg/min NE (n=6; NE2-C), 4 µg/kg/mi_n NE 
(n=6; NE4-C) or 6 µg/kg/min NE (n=6; NE6-C) then returned to their cages. 
In a second series of experiments, myocardial responsiveness to a-adrenergic 
receptor stimulation was investigated immediately after 4µg/kg/min NE infusion 
(n=5) and at 48 hours post 4 µg/kg/min NE (n=6) or saline (n=7) infusion. 
2. Isolated Heart Preparation 
Following administration of sodium pentobarbital (30 mg/kg, IV) and heparin 
(500 IU/kg), the thoracic cavity was opened. The heart was quickly excised and 
immersed in cold heparinized Krebs-Henseleit buffer (KHB) modified with 11 mM 
glucose. The aorta was cleaned of fat and connective tissue. The heart was weighed 
and was placed on a non-recirculating, constant flow Langendorff apparatus. Flow 
rate was 10 ml/min/g wet weight. The KHB was warmed by Graham condensers and 
constant temperature circulator to maintain intraventricular temperature at 37 ± 
0.5°C. A right atrial bipolar electrode was used to pace hearts at 220 beats/min. The 
pulmonary artery was cannulated to hinder flow of effluent into the left ventricle. A 
small cannula was inserted through the apex of the left ventricle to prevent fluid 
accumulation within the chamber. To measure left ventricular pressure (L VP), a 
fluid-filled latex balloon was inserted into the left ventricle through the mitral valve 
orifice. The balloon was connected to a Statham pressure transducer with a 9 cm 
length of polyethylene tubing. A Hamilton syringe positioned between the balloon and 
pressure transducer allowed for changes in balloon volume. After securing the 
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balloon in the LV, LV end-diastolic pressure was maintained at 5 mmHg. Hearts 
were allowed to equilibrate for 30 minutes 
3. Tau 
Tau, the time constant for isovolumic relaxation, was measured in experiments 
assessing responsiveness to a-receptor stimulation. The beginning of isovolumic 
relaxation was defined as 75 % peak systolic pressure (17). Tau was the time required 
for ventricular pressure at 75 % peak systolic pressure to be reduced by lie. 
4. Protocol 
In the first series of experiments, hearts were perfused with KHB plus the a-
receptor antagonist phentolamine (Regitine, 10-6 M). a-Adrenoceptor blockade was 
tested with 10-7 M methoxamine. Receptor blockade was considered complete when 
there was no change in ventricular function or perfusion pressure when the heart was 
challenged with the appropriate agonist. Hearts were perfused with increasing, 
cumulative concentrations of dobutamine (10-9 - 10-6 M). Steady state LVP and LV 
dP/dlm.x were recorded at baseline, i.e., in the presence of a-receptor blockade, and 
at each concentration of dobutamine. 
To assess a-adrenoceptor responsiveness, other hearts were subjected to 
decreasing concentrations of NE (10-6 - 10-7 M). After a twenty minute wash, 10-6 M 
timolol was added to the perfusate. /j-Receptor blockade was tested with isoproterenol 
(1Q·7 M). Hearts were re-exposed to NE (10-6 - 10-7 M). LVP and LV dP/dlm.x were 
measured before exposure to NE and after two minutes at each NE concentration. 
Control measurements of tau were also recorded. 
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5. Data Analysis 
All values are expressed as mean ± SEM. An analysis of variance was used 
to test for differences between groups. The Student-Newman Keuls test was used to 
isolate differences. Values of p < 0.05 were considered statistically significant. 
C. RESULTS 
Baseline peak L VP for hearts isolated after the 90 minute infusion was 93 .4 
± 2.6 mmHg for SAL compared to 84.8 ± 3.4, 78.2 ± 5.7 and 80.8 + 8.2 mmHg 
for NE2-A, NE4-A and NE6-A, respectively. Although peak LVP's were slightly 
lower in hearts from NE treated rabbits, there were no significant differences between 
the groups. At 48 hours post infusion, NE6-C peak LVP of 80.5 + 4.4 mmHg was 
significantly lower than SAL (93.4 + 2.6 mmHg), NE2-C (97.5 ± 5.1 mmHg) and 
NE4-C (95.8 ± 4.7 mmHg). 
NE treated hearts increased L VP in response to increasing concentrations of 
dobutamine (Figure 5-1, panels A and B). Peak LVP generated by hearts acutely 
treated with NE was lower than SAL at each concentration, but the difference was 
significant only at 10-7 M dobutamine (panel A). Forty-eight hours post infusion, 
there were no differences in L VP for NE2-C, NE4-C and SAL at any concentration 
of dobutamine (panel B). NE6-C peak LVP was lower than SAL, NE2-C and NE4-C 
in the presence of dobutamine but NE6-C was significantly lower than SAL and NE2-
C only at 10-7 M. Changes in L VP with exposure to dobutamine were less than SAL 
in NE2-A at 10-7 Mand in NE4-C at 10-7 Mand 10-6 M (Table 5-1). Changes in LVP 
121 
in other groups were not significantly different from SAL at any dobutamine 
concentration. 
Baseline LV +dP/d~ of NE treated hearts were not different than SAL 
immediately after or at 48 hours post infusion (Figure 5-2, panels A and B). All 
hearts increased LV +dP/d~ in response to dobutamine yet LV +dP/d~ of NE2-
A, NE4-A and NE6-A were significantly lower than SAL at 10-8 M, 10-7 Mand 10-6 
M dobutamine (Figure 5-2, panel A). Similarly, the change in LV +dP/d~ was 
significantly less than SAL for all NE-A groups at 10-7 and lo-6 M dobutamine (Table 
5-1). In chronic experiments, NE4-C and NE6-C LV +dP/d~ were significantly 
lower than SAL at 10-6 M dobutamine (Figure 5-2, panel B) but the mmHg/sec 
increase in LV +dP/d~ was significantly less than SAL only in NE4-C (Table 5-1). 
In acute experiments, LV -dP/dt:.n.x was depressed in NE2-A, NE4-A and NE6-
A at baseline and 10-8 M through 10-6 M dobutamine compared to SAL (Figure 5-3, 
panel A). Two days post infusion (Figure 5-3, panel B), NE6-C LV -dP/d~ was 
reduced at baseline and at 10-6 M dobutamine while NE4-C LV -dP/dt:.n.x was lower 
than SAL at 10-6 M dobutamine. However,changes from baseline LV -dP/d~ when 
hearts were perfused with dobutamine were similar in SAL and NE treated hearts 
(Table 5-1). 
Left ventricular pressure developed by NE2 at baseline and in the presence of 
dobutamine showed improvement within 48 hours of NE infusion. NE4-C L VP was 
significantly greater than NE4-A at baseline and at 10-8 M dobutamine (Figure 5-1). 
NE2-C LV +dP/dt:.n.x was greater than NE2-A at 10-7 and 10-6 M dobutamine. NE4-C 
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FIGURE 5-1 
CHANGES IN LEFT VENTRICULAR PRESSURE WITH INCREASING· 
CONCENTRATIONS OF DOB UT AMINE 
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DOBUTAMINE (M) 
Effect of increasing dobutamine concentrations on left ventricular pressure 
(LVP) development in hearts from rabbits infused with saline (SAL) or norepinephrine 
at 2 (NE2), 4 (NE4), and 6 (NE6) µg/kg/min. Panel A: LVP generated by hearts 
isolated immediate! y after infusion (-A). Panel B: L VP developed in hearts isolated 
48 hours post infusion (-C). End diastolic pressure is 5 mmHg. Values are presented 
as mean ± SEM. B: baseline function. * p<0.05 compared to SAL,# p<0.05 
compared to NE2-C, and O p<0.05 compared to NE4-C. 
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FIGURE 5-2 
DOBUTAMINE LV +dP/dt DOSE-RESPONSE CURVES 
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DOBUTAMINE (M) 
Effect of dobutamine on LV +dP/dt generated by hearts isolated immediately 
post infusion (panel A) or at two days (panel B). End diastolic pressure is 5 mmHg. 
LV +dP/dt, first derivative of LVP; other abbreviations as in Figure 5-1. * 
Significantly different from SAL (p < 0.05). 
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FIGURE 5-3 
DOBUTAMINE LV -dP/dt DOSE-RESPONSE CURVES 
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Effect of increasing concentrations of dobutamine on the first derivative of left 
ventricular pressure decline (LV -dP/dt) in hearts isolated immediately after (panel A) 
or two days post (panel B) saline or norepinephrine infusion. Diastolic pressure = 5 
mmHg. Abbreviations as in Figure 5-1. * p<0.05 compared to SAL. 
TABLE 5-1 
CHANGE IN LEFT VENTRICULAR FUNCTION WITH DOBUTAMINE 
LVP (mmHg) 10-1 M DOB 10-6 M DOB 
SAL 13.4 ± 1.3 35.5 + 2.7 
NE2-A 5.8 ± 1.3* 27.9 + 3.9 
NE4-A 9.0 + 0.6 37.0 ± 2.0 
NE6-A 9.8 ± 3.3 35.6 ± 7.2 
NE2-C 12.5 ± 1.5 32.1 ± 3.1 
NE4-C 6.4 ± 1.1 * 24.8 ± 1.5* 
NE6-C 12.8 + 1.4 34.5 ± 3.3 
LV +dP/dt (mmHg/sec) 10-7 M DOB 10-6 M DOB 
SAL 454.7 + 66.3 1734.0 ± 165.6 
NE2-A 136.6 + 27.0* 1064.7 ± 99.7* 
NE4-A 220.9 + 32.0* 1242.9 ± 95.8* 
NE6-A 220.7 ± 61.7* 1043.2 ± 160.5* 
NE2-C 431.8 ± 23.2 1330.3 + 51.9 
NE4-C 219.0 + 34.7* 1139.5 + 24.0* 
NE6-C 358.7 + 45.4 1312.4 + 63.4 
LV -dP/dt (mmHg/sec) 10-7 M DOB 10-6 M DOB 
SAL -205.7 ± 26.8 -745.9 + 69.8 
NE2-A -112.0 ± 36.2 -549.4 ± 72.5 
NE4-A -111.4 ± 15.3 -559.9 ± 51.2 
NE6-A -176.8 ± 51.3 -587.0 ± 108.9 
NE2-C -172.2 ± 42.4 -623.4 ± 50.2 
NE4-C -114.4 + 14.2 -460.1 ± 24.2* 
NE6-C -180.1 + 10.0 -658.8 ± 15.5 
Listed values are means ± SEM for the increase in ventricular function above 
baseline values. DOB: dobutamine; other abbreviations as in Figure 5-1. 
*p<0.05 compared to SAL. 
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generated a higher LV +dP/d1max than NE4-A at baseline and concentrations of 
dobutamine to 10-7 M (Figure 5-2). Diastolic function of NE2 and NE4, as measured 
by LV -dP/dtmm was improved at baseline and in the presence of dobutamine by the 
second day after the infusion (Figure 5-3). Systolic and diastolic function did not 
improve over the 48 hour period in NE6. 
In the second series of experiments, LVP was depressed in NE4-A (73. 7 ± 
3.4 mmHg) and NE4-C (75.8 ± 2. 7 mmHg) under control conditions when compared 
to SAL (91.7 ± 4.9 mmHg) (Figure 5-4). LVP increased significantly in all groups 
in response to 10-6 M NE, although, pressures developed by NE4-A and NE4-C were 
still lower than SAL. Perfusing hearts with KHB + timolol did not change LVP's. 
In the presence of timolol, 10-6 M NE increased L VP slightly, but insignificantly, in 
all groups. 
There were no differences in control LV +dP/d1max between the groups (Figure 
5-5) but control LV -dP/d1max of NE4-A and NE4-C was significantly lower than SAL 
(Figure 5-6). NE (10-6 M) increased LV +dP/d1max and LV -dP/d1max significantly in 
all groups. In the presence of timolol, NE4-A LV +dP/dfuwc was 1057.4 ± 38.2 
mmHg/sec and was significantly lower than SAL (1342 ± 60. 7 mmHg/sec) and NE4-
C (1306.7 ± 58.4). LV -dP/d1max generated in the presence of timolol was not 
different from control values. With the 13-adrenoceptors blocked, NE increased LV 
+dP/d1max slightly but insignificantly in all groups. Similarly, LV -dP/d1max generated 
by a-receptor stimulation was not significant except in NE4-A in presence of lQ-6 M 
NE. 
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FIGURE 5-4 
NOREPINEPHRINE INDUCED CHANGES IN VENTRICULAR PRESSURE 
BEFORE AND AFTER /3-ADRENERGIC RECEPTOR BLOCKADE 
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Left ventricular pressure (L VP) developed in the presence of norepinephrine 
(NE) before and after {3 adrenergic receptor blockade by timolol (TIM). Hearts were 
isolated immediately after 4 µg/kg/min NE infusion (NE4-A) or 48 hours after saline 
(SAL) or 4 µg/kg/min infusion (NE4-C). • p<0.05 as compared to SAL,# p<0.05 
as compared to corresponding control pressure. 
FIGURE 5-5 
CHANGES IN LV +dP/dt INDUCED BY NOREPINEPHRINE 
BEFORE AND AFfER /3-RECEPTOR BLOCKADE 
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Effect of norepinephrine on the first derivative of LVP (LV +dP/dt) before 
and after the addition of TIM. Refer to Figure 5-4 for additional abbreviations. "' 
Significantly different than SAL (p < 0.05), # Significantly different from control 
value, 0 Significantly different from NE4-C. 
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FIGURE 5-6 
CHANGES IN LV -dP/dt INDUCED BY NOREPINEPHRINE 
BEFORE AND AFfER JS-RECEPTOR BLOCKADE 
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Effect of norepinephrine on the first derivative of LVP decline (LV -dP/dt) 
before and after ,S-receptor blockade by timolol. Abbreviations as in Figure 5-4. * 
p<0.05 when compared to SAL,# p<0.05 compared to NE4-A, 0 p<0.05 compared 
to control value. 
LVP 
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LV +dP/dt 
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TABLE 5-2 
CHANGE IN VENTRICULAR FUNCTION DUE TO 
a-RECEPTOR STIMULATION 
NE 10·7 M 
7.3 ± 2.2 
8.4 ± 1.4 
6.2 ± 1.6 
175.9 + 46.1 
161.5 + 28.8 
169.0 + 53.9 
-124.6 + 38.6 
-149.1 ± 27.1 
-34.7 ± 25.5 
NE 5 X 10-7 M 
10.6 ± 2.0 
13.0 ± 0.8 
6.3 + 1.6 
280.6 ± 46.6 
236.2 ± 7.9 
293.9 ± 52.8 
-157.5 ± 22.4 
-210.5 ± 23.8 
-61.1 ± 26.1*# 
NE 10-6 M 
10.9 + 2.2 
10.0 + 2.3 
3.5 + 1.6* 
275.9 ± 42.6 
182.4 ± 34.3 
288.5 ± 48.2 
-157.1 + 24.8 
-397.5 + 29.8* 
-75.4 ± 18.7*# 
Hearts were perfused with norepinephrine (NE) in the presence of timolol. Data 
are expressed as mean ± SEM. Abbreviations as in Figure 5-4. * p<0.05 
compared to SAL. # p<0.05 compared to NE4-A. 
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Changes in LVP and LV +dP/dt..n.x due to a-adrenoceptor stimulation were 
similar among the groups however, the LVP generated by NE4-C was significantly 
less than SAL at 10-6 M NE (Table 5-2). Changes in diastolic function, as measured 
by LV -dP/dt..n.x, were lower in NE4-C at all NE concentrations compared to SAL and 
NE4-A. The increase in NE4-C LV -dP/dt..n.x was significantly less than SAL and 
NE4-A at both 5 x 10-7 M and at 10-6 M NE. The change in NE4-A LV -dP/dt..n.x was 
significantly greater than SAL and NE4-C at the highest NE concentration. 
Tau, an additional measure of diastolic function, was significantly depressed 
in NE treated hearts under control conditions. Tau was 22.0 ± 0.9 msec for SAL 
hearts and 24.9 ± 0.7 msec and 24.9 ± 0.6 msec for NE4-A and NE4-C, 
respectively. 
D. DISCUSSION 
Exposure of tissue to an adrenergic agonist results in a rapid desensitization 
of adrenergic receptor mediated events. Hayes et al. (10) reported that isoproterenol 
(ISO) infusion attenuated subsequent myocardial inotropic responses to Iso; a /3-
adrenergic agonist, but not to phenylephrine, an a-receptor agonist. Chang et al. (5) 
have also shown a selective desensitization of rat {3-adrenergic receptors following a 
NE infusion with no change in the responsiveness of a-adrenergic receptors. In 
contrast, Corder et al. (7) reported a decrease in {3-receptors and a-receptors after ISO 
injection. This difference in the results reported by these investigators may be related 
to the dose of catecholamines administered. 
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Schulze et al. (18) reported that adenylate cyclase isolated from necrotic areas 
of the rat left ventricle previously damaged by an injection of high dose ISO, was 
unable to increase enzyme activity to the same degree as the cyclase from normal 
tissue with subsequent ISO stimulation. The decline in the ability to stimulate 
adenylate cyclase activity by ISO may have been due to receptor uncoupling and 
internalization (5, 16). However, several investigators have suggested that high dose 
catecholamines or prolonged exposure to catecholamines may induce a defect in the 
G protein or adenylate cyclase enzyme (7,22). 
In our study, it was hypothesized that desensitization of /3-adrenergic receptor-
adenylate cyclase system or alteration in effector proteins with catecholamine 
administration would result in a depressed ability of dobutamine, a /3-receptor agonist, 
to increase ventricular function after NE infusion. Our data demonstrated that hearts 
isolated from rabbits immediately after or 48 hours post NE administration, increased 
LVP and LV -dP/dlm.x the same amount as SAL hearts in response to /3-receptor 
stimulation. These data suggest that the /3-receptor was not functionally uncoupled 
from adenylate cyclase. 
The ability of /3-receptor stimulation to increase LV +dP/dlm.x in hearts acutely 
injured by NE was impaired. The findings of this study suggest that NE treatment 
acutely altered the formation of cross-bridges between actin and myosin, cross-bridge 
motion, rephosphorylation of the myosin head by ATP or the dissociation of the 
actomyosin complex. Conceivably, the maximal number of cross-bridges formed was 
not changed since the increase in L VP of NE treated hearts was not different than 
133 
SAL. Brown and Hudlicka have reported that hearts of NE treated rabbits increased 
+dP/d1uwt to the same degree as saline controls when challenged with intravenous NE 
48 hours after treatment (4). Similarly, in our study the increase in LV +dP/d1uwt 48 
hours after the infusion was not different among the groups. 
Increase in cardiac function mediated by ai-adrenoceptors in the presence of 
~-receptor blockade has been demonstrated in various mammals (1,2,20,23). In this 
study we also reported a slight, but insignificant, increase in left ventricular systolic 
and diastolic function with ai-receptor stimulation. At the onset of these experiments 
it was proposed that a-receptor mediated changes in ventricular function would be 
greater after NE administration. However, changes in ventricular systolic 
performance with a 1-receptor stimulation were not altered either acutely or chronically 
after NE treatment. These results are in agreement with data reported by Hayes et 
al. (10) which showed that responsiveness of the rat myocardium to a-adrenergic 
agonists was not changed following a prolonged ISO infusion. 
In summary, the results presented in this chapter indicate that (1) the 
responsiveness of the NE cardiomyopathic heart to ~-adrenergic receptor stimulation 
was not impaired during these experiments and (2) the a 1-adrenergic receptor system 
was not more important in increasing left ventricular function in the rabbit after NE-
induced injury. Furthermore the results suggest that NE treatment acutely altered a 
step in cross-bridges formation or cycling. 
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CHAPTER VI 
EFFECT OF cx-TOCOPHEROL AND SELENIUM PRETREATMENT 
ON NOREPINEPHRINE-INDUCED CARDIOTOXICITY 
A. INTRODUCTION 
Excessive endogenous or exogenous catecholamines produce multifocal lesions 
within the myocardium (65). Characteristic damage includes edema, contraction band 
formation, myofibrillar disintegration, cellular infiltration and necrosis (18,64,65,67). 
The etiology of this injury has not been fully elucidated but multiple mechanisms have 
been suggested (50). Several investigators have proposed that products of 
catecholamine autoxidation are involved in the cardiotoxicity of catecholamines 
(27,43,45,53). 
The autoxidation of catecholamines generates free radicals and unstable, 
cytotoxic metabolites (5,24,53,58). Free radicals cause tissue damage by reacting 
with polyunsaturated lipids within membranes (10,35,48), nucleotides in DNA (35), 
or sulfhydryl bonds in proteins (35,40). The peroxidation of cellular membranes 
initiated by free radicals (35 ,52) alters membrane structure, integrity and function 
(32,34,37,60). Oxidative metabolites induce ultrastructural damage similar to that 
produced by high dose catecholamines (14,71,72,74). Enzyme activity (57,58), 
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mitochondrial function (14,59) and ventricular function (14, 71-73) are also impaired 
by the metabolites of catecholamine oxidation. 
a-Tocopherol, a constituent of vitamin E, is an antioxidant (7) which scavenges 
free radicals and terminates peroxidation of lipids within biological membranes 
(9, 19,21,61). Singal et al. have shown that vitamin E protected against the deleterious 
effects of isoproterenol in the rat (53). These investigators have also demonstrated 
increased lipoperoxidation in the rat myocardium with ISO that is prevented by a-
tocopherol pretreatment (52). Selenium is an essential trace element and integral 
component of glutathione peroxidase (28,62). Selenium-dependent glutathione 
peroxidase is an enzyme that reduces oxidized lipids. The administration of selenium 
has been shown to increase glutathione peroxidase activity and afford protection 
against lipid peroxidation (2,12,17,26). 
Adequate amounts of selenium-dependent glutathione peroxidase and a-
tocopherol are essential for normal cellular physiology particularly if tissues are 
exposed to substances which directly or indirectly promote lipid peroxidation. If 
catecholamine cardiotoxicity is mediated by lipid peroxidation, the administration of 
a-tocopherol and selenium should protect the myocardium from injury. The purpose 
of this study was to determine if a two week pretreatment with a-tocopherol and 
selenium would protect the rabbit myocardium from norepinephrine induced injury. 
B. METHODS 
1. Norepinephrine-Induced Cardiomyopathy 
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Thirteen male, New Zealand white rabbits (2.2 kg) were treated 
subcutaneously with a-tocopherol (25.0 mg; BO-SE, Schering Co., U.S.A.) and 
selenium (0.5 mg) every other day for two weeks. Twenty-four hours after the last 
treatment rabbits were anesthetized with intravenous sodium pentobarbital (30 mg/kg). 
Saline (SAL-E; n=6) or 4 µg/kg/min norepinephrine bitartrate (NE4-E; n=7) was 
infused for 90 minutes via the marginal ear vein. Infusion rate was constant at 0.238 
ml/min. Seventeen rabbits not receiving vitamin pretreatment were infused with saline 
(SAL; n=ll) or NE (NE4; n=6). Ventricular function was studied two days post 
infusion. 
When the rabbits were deeply anesthetized (sodium pentobarbital, 30 mg/kg, 
IV), heparin (500 IU/kg) was administered and the thoracic cavity was opened. The 
heart was quickly excised and placed in cold heparinized Krebs-Henseleit buffer 
modified with 11 mM glucose (KHB; pH 7.4). The aorta was cleaned of fat and 
connective tissue and the heart was weighed. The heart was placed on a non-
recirculating, constant flow Langendorff apparatus and perfused with KHB at 10 
ml/min/g wet weight. KHB was warmed by Graham condensers and constant 
temperature circulator to maintain intraventricular temperature at 37 + 0.5°C. A 
right atrial bipolar electrode was used to pace hearts at 220 beats/min. The 
pulmonary artery was cannulated to hinder flow of effluent into the left ventricle. A 
small cannula was inserted through the apex of the left ventricle to prevent fluid 
accumulation within the chamber. To measure left ventricular pressure (L VP), a 
fluid-filled latex balloon was inserted into the left ventricle through the mitral valve 
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orifice. The balloon was connected to a Statham pressure transducer with 
polyethylene tubing. A Hamilton syringe positioned between the balloon and pressure 
transducer allowed for changes in balloon volume. After securing the balloon in the 
L V, balloon volume was adjusted so L V end-diastolic pressure (L VEDP) was 5 
mmHg. 
2. Protocol 
After a 30 minute equilibration period, L VEDP was varied from O to 25 
mmHg (5 mmHg steps) then reset to 5 mmHg. Baseline LVP and LV dP/d~ were 
recorded at each LVEDP. Hearts were exposed to cumulative, increasing 
concentrations of NE 00-10 - 10-6 M). At each NE concentration, LVEDP was varied 
from O to 25 mmHg (5 mmHg increments) then reset to 5 mmHg. Steady state LVP 
and LV dP/d~ were recorded. 
3. Histology 
At the end of several experiments, the atria and right ventricular free wall were 
dissected from the left ventricle. A midlevel transverse section of L V and septum was 
fixed in 10% buffered formalin and stained with hematoxylin and eosin. LV sections 
were viewed (blindly) to verify the presence or absence of myocardial injury. This 
injury was characterized by edema, loss of nuclei, focal myofiber destruction, and the 
presence of cellular infiltration. Sections were assessed by a pathologist who had no 
knowledge of experimental design. 
4. Data analysis 
All values are expressed as mean ± SEM. An analysis of variance (ANOVA) 
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was used to test for differences between groups. The Student-Newman Keuls test was 
used to isolate differences. Values of p < 0.5 were considered statistical_ly 
significant. 
C. RESULTS 
1. Heart Weights 
Body weights were similar in a-tocopherol and selenium treated and untreated 
rabbits. The weights of cardiomyopathic hearts (NE4 5.0 ± 0.1 g; NE4-E 5.5 ± 0.2 
g) were not different than normal hearts (SAL 4.9 ± 0.2 g; SAL-E 5.1 ± 0.2 g). 
2. Left Ventricular Function 
There was no difference in baseline LVP for LVEDP's of 5 to 25 mmHg 
among the groups (Figure 6-1). At EDP of 0 mmHg, LVP developed by NE4-E was 
significantly lower than SAL and NE4. Increases in LVP with changing LVEDP were 
similar in all groups. 
Positive LV dP/dt.n.x was reduced significantly in hearts from rabbits treated 
with a-tocopherol and selenium (Figure 6-2) as compared to SAL at all EDP's. At 
5 mmHg EDP, LV +dP/dt.n.x was 1498.0 ± 67.7 and 1348.6 ± 97.5 mmHg/sec for 
SAL-E and NE4-E respectively, compared to 1762.4 ± 95.9 mmHg/sec for SAL and 
1635.6 ± 82.6 mmHg/sec for NE4. Negative LV dP/d~x also was depressed 
significantly in NE4, SAL-E and NE4-E compared to SAL (Figure 6-3). 
Left ventricular systolic function improved in all groups in response to 
increasing concentrations of NE (Figure 6-4). NE4-E LV +dP/dt.n.x was lower than 
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FIGURE 6-1 
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from rabbits infused with 4 µg/kg/min norepinephrine. SAL-E: hearts from rabbits 
infused with saline after pretreatment with cx-tocopherol and selenium. NE4-E: rabbits 
infused with 4 µg/kg/min norepinephrine after pretreatment with cx-tocopherol and 
selenium. * indicates a significant difference compared to SAL. # indicates a 
significant difference compared to NE4. 
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Mean ± SEM for the first derivative of increasing left ventricular pressure, 
LV +dP/dt.nax, as a function of end-diastolic pressure. Abbreviations as in Figure 6-
1. * indicates a significant difference from SAL. # indicates a significant difference 
from NE4. 
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Mean ± SEM for the first derivative of decreasing left ventricular pressure, 
LV -dP/dlmax, as a function of end-diastolic pressure. Abbreviations as in Figure 6-1. 
* p<0.05 compared to SAL. 
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Mean ± SEM values for the first derivative of increasing left ventricular 
pressure (LV +dP/dt_J at baseline (B) and in response to increasing concentrations 
of norepinephrine. Measurements recorded at 5 mmHg end diastolic pressure. Other 
abbreviations as in Figure 6-1. * indicates a significant difference from SAL. 
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SAL at baseline and at NE concentrations to 10-7 M. At 10-6 M NE, LV +dP/d½nax 
was virtually the same in all groups. Increased diastolic function was also ob~erved 
during perfusion with NE (Figure 6-5). At baseline and NE concentrations to 10 -7 
M, LV -dP/d½nax was significantly lower in NE4 and NE4-E compared to SAL. There 
was no difference in LV -dP/dt:.n.x among the groups at 10-6 M NE. 
3. Histology 
Histological sections showed no abnormalities in the left ventricles of SAL and 
SAL-E. Edema, contraction bands, loss of myofibrillar material and nuclei and 
cellular infiltrates were observed in NE treated hearts. This histological injury was 
not quantified. 
D. DISCUSSION 
The results of the present study show that L V diastolic function is depressed 
two days post NE infusion. Treating rabbits for two weeks with a-tocopherol and 
selenium did not protect the myocardium from NE-induced injury. Surprisingly, 
treatment significantly decreased baseline L V function. However, all groups increased 
ventricular function similarly in response to increasing concentrations of NE. At the 
highest concentration of NE, there was no difference in L V diastolic and systolic 
function among the groups. 
Circulating NE is normally inactivated by tissue uptake with subsequent storage 
and metabolism, conjugation, or urinary excretion of the free catecholamine. During 
prolonged infusion of high dose NE, these mechanism may be saturated leaving more 
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free catecholamine to undergo autoxidation. Spontaneously oxidized isoproterenol 
(14,72), adrenochrome (54,57-59,74) and free radicals (29,47) damage. the 
myocardium and decrease left ventricular function. Free radicals attack unsaturated 
bonds of membrane phospholipids, abstract an hydrogen ion and initiation lipid 
peroxidation (11,35,46,62). Membrane permeability (6,30,37) and fluidity (16,20) 
are altered by lipoperoxidation. Additionally, mitochondrial and microsomal enzymes 
(46,60,70) and membrane ATPases (49) are inactivated. Alterations in enzyme 
function may be due to protein damage and subsequent polymerization or due to 
changes in the phospholipid microenvironment (23,25). Noronha-Dutra et al. (43) 
have shown that incubation of isolated heart cells with plasma from rats given high 
dose epinephrine induced the formation of membrane microblebs and microvilli. 
Sarcolemmal permeability was also increased. These changes in membrane 
characteristics are evidence of lipid peroxidation. 
a-Tocopherol, an effective chain-breaking antioxidant (8,61), terminates lipid 
peroxidation in sarcolemmal and intracellular membranes (22,63) and preserves 
membrane structure and function (34). Glutathione peroxidase reduces lipid 
hydroperoxides formed by peroxidation to hydroxy acids (38,51,61,62) preventing 
these peroxides from altering membrane structure and function (26). Tappel has 
reported that selenium-dependent glutathione peroxidase activity increased with lipid 
peroxidation (62). Additionally, selenium administration was reported to increase 
glutathione peroxidase activity (2, 12, 17 ,26). Pretreatment with a-tocopherol and 
selenium should protect myocardial membranes from peroxidative damage. Singal et 
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al. (53) reported that pretreating rats with vitamin E (10 mg/kg/day) for two weeks 
protected the myocardium from isoproterenol induced damage and reduced- high 
energy phosphate levels. A water-soluble analogue of vitamin E, Trolox C, has also 
been shown to be effective in preventing deleterious effects of isoproterenol in 
neonatal rat heart cultures (45). In contrast, the administration of selenium and 
vitamin E to pigs did not protect against myocardial damage with isoproterenol but did 
prolong survival (66). In the present study we have shown that pretreatment with a-
tocopherol and selenium did not protect the rabbit heart exposed to high dose 
norepinephrine. In fact, treatment with these agents tended to decrease baseline 
ventricular function (Figures 1, 2, and 3). 
The cause of depressed baseline ventricular function in pretreated animals 
(SAL-E) compared to SAL is unclear. The incidence of a-tocopherol toxicity is very 
low (4,39,44,68). Rabbits, cats, dogs and monkeys can tolerate 200 mg/kg body 
weight without toxic effects (4). When dosage exceeded 1 g/kg body weight per day, 
coagulation problems developed possibly due to vitamin E inhibition of platelet 
aggregation or increased requirement for vitamin K (1,4,41,55,56). Vitamin K 
supplementation has been reported to alleviate the coagulation problems in the rat 
(68). Megadose vitamin E has been associated with skeletal muscle degeneration (15) 
and a necrotizing, nonprogressive skeletal myopathy with unusual paracrystalline 
inclusion bodies in humans (3). Cardiac toxicity has not been reported. In our study, 
25 mg a-tocopherol acetate administered every other day for two weeks was 
significantly below toxic levels. Left ventricular sections from a-tocopherol and 
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selenium pretreated, saline infused rabbits (SAL-E) had no pathology. 
In contrast to cx-tocopherol, selenium has been shown to be toxic in 
experimental animals. Characteristic signs of acute selenosis include "garlic breath", 
lethargy, excessive salivation, vomiting, dyspnea, muscle tremors and respiratory 
failure (13,69). Endocarditis and myocarditis have also been observed. In rabbits, 
Levine and Flaherty (36) reported an LD75 of 1. 8 mg selenium/kg body weight for 
subcutaneous administration. Chronic selenosis is characterized by dermatitic lesions, 
anorexia with weight loss, and increased serum transaminases and alkaline 
phosphatase (13,33). Rabbits used in this study did not exhibit signs of acute or 
chronic selenium toxicity. Body and heart weights were not different between treated 
and untreated animals. Histological sections of the left ventricle from rabbits treated 
with cx-tocopherol and selenium (SAL-E) had no signs of endocarditis or myocarditis. 
Serum levels of transaminase and alkaline phosphatase were not measured. 
Vitamin E administered to rabbits in conjunction with selenium increased the 
LD50 from 2.53 mg/kg body weight to 2. 73 mg/kg (69). This reduction in selenium 
toxicity (31,42,69) may be the result of vitamin E decreasing tissue selenium 
concentrations (42). In the present study, the administration of cx-tocopherol may 
have decreased any overt toxic signs of selenium so they were not observed by the 
investigators. Alternatively, myocardial selenium or cx-tocopherol concentrations 
elevated above some optimum may intrinsically depress myocardial function. 
The data presented in this study shows that the administration of cx-tocopherol 
and selenium every other day for two weeks does not protect the rabbit myocardium 
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from NE induced injury. In fact, pretreatment depressed baseline function. However, 
it should be noted that this pretreatment did not significantly exacerbate the functional 
injury created with high dose NE. 
Further investigation is needed to separate the effects of a-tocopherol and 
selenium on cardiac function and to determine if the protective effect of these agents 
against catecholamine injury is species specific. The role of oxidized metabolites and 
lipid peroxidation in the etiology of catecholamine cardiomyopathy remains to be 
elucidated. 
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CHAPTER VII 
MYOCARDIAL BLOOD FLOW DURING AND AFfER A 
HIGH DOSE NOREPINEPHRINE INFUSION 
A. INTRODUCTION 
Catecholamines can modulate myocardial blood flow directly by the activation 
of adrenergic receptors within the coronary vasculature (3,6,9, 10,20) or indirectly by 
stimulating myocardial function and metabolism (3,15,16,24). Stimulation of the (3-
adrenergic receptor produces dilation of coronary vessels (14,23,24). Similarly, 
intracoronary infusion of isoproterenol (ISO) has been shown to increase blood flow 
to the canine myocardium in a dose dependent manner (9). Blockade of the (31 and 
{32-adrenergic receptors eliminated this response. 
Under resting conditions, the cx-adrenergic receptors mediate a tonic 
vasoconstrictor tone in the coronary vasculature. Further vasoconstriction of coronary 
vessels with the administration of catecholamines, particularly in the presence of (3-
receptor blockade, has been demonstrated in several laboratories (1,16,18,22,25,26). 
In experiments where the dosage of a catecholamine was excessive, total myocardial 
blood flow was reduced below control with significantly less flow reaching the 
endocardium (4,8,9,21,27). Simons and Downing (21) reported decreased myocardial 
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blood flow during an infusion of norepinephrine (NE) at a dose known to induce 
myocardial injury. It was suggested that coronary vasoconstriction and localized 
ischemia mediated by a-adrenergic receptor stimulation contributed to catecholamine-
induced cardiac injury. 
If the cardiac injury induced by high dose catecholamines is the result of 
ischemia, perfusion abnormalities may develop. Kloner et al. (11, 12) have shown 
abnormal myocardial perfusion following a temporary coronary artery occlusion. This 
defect, the no-reflow phenomenon, is characterized by poor perfusion or possibly 
regions of no perfusion in the myocardium after an ischemic insult (5, 11). 
The purpose of this study was to determine if the myocardium was perfused 
normally after a 40 minute NE infusion (4 µg/kg/min). Simons and Downing have 
reported that coronary blood flow was decreased at 40 minutes with the administration 
of NE (3 µg/kg/min) (21). Flow changes for a longer time course have not been 
investigated. In the present study, a NE concentration higher than that used by 
Simons and Downing was chosen in attempt to exacerbate the ischemic response. 
Coronary blood flow was measured at control, 40 minutes of NE infusion and at one 
hour and two days post infusion to further characterize the response. 
B. METHODS 
1. Norepinephrine-Induced Cardiomyopathy 
Nineteen New Zealand white rabbits were anesthetized with sodium 
pentobarbital (30 mg/kg IV) and infused with saline or norepinephrine (NE; 
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4µg/kg/min) for 40 minutes. Coronary blood flow was measured at O and 40 minutes 
infusion and at one hour post-infusion in seven NE treated rabbits (NE4-A) and seven 
saline controls (SAL-A). Five NE treated rabbits (NE4-C) were returned to their 
cages post-infusion and myocardial blood flow was measured 48 hours after infusion. 
2. Myocardial Blood Flow 
After sodium pentobarbital anesthesia (30 mg/kg IV), the trachea was 
cannulated and the rabbit was ventilated with room air. Body temperature was 
monitored and maintained at 38 ± 1 °C with a heat exchanger and heating pad. 
Femoral arteries were cannulated with polyethylene catheters. One arterial cannula 
was connected to a Statham pressure transducer for continuous monitoring of arterial 
blood pressure. The second arterial cannula allowed for withdrawal of reference 
blood samples during microsphere injection. In acute experiments, a femoral vein was 
cannulated for infusion of NE or saline. After a left thoracotomy, the left atrial 
appendage was cannulated. Standard lead II ECG was recorded. 
Radiolabeled 15 µm spheres (Ce-141, Nb-95, Ru-103, and Sr-46 3M Co, New 
England Nuclear) were suspended in 10% dextran with 0.05 % Tween 80. 
Microsphere vials were sonicated for 20 minutes before use and were vigorously 
agitated immediately prior to injection. For each flow measurement, approximately 
1 x 106 microspheres were injected into the left atrium over 20-30 seconds. Reference 
blood sample was withdrawn from the femoral artery at a rate of 3-4 ml/min. Blood 
withdrawal began 30 seconds before injection of microspheres and continued for 30-40 
seconds post-injection. The reference blood sample was put into labeled counting 
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tubes. The withdrawal syringe was rinsed and the rinse was added to respective blood 
sample counting tubes. At the termination of the experiment, the heart was removed. 
The right ventricular (RV) free wall and left ventricle (L V) were isolated and fixed 
for 24-48 hours in a 10% formalin solution. The RV was weighed and placed in 
counting tubes. The LV was cut into 5-6 rings. Each ring was separated into 
endocardial and epicardial halves via a circumferential cut at a point midway between 
the epicardial and endocardial surfaces. Endocardial and epicardial samples were 
weighed and placed in separate plastic counting tubes. Radioactivity of the 
myocardium and reference blood tissue samples was counted by a Nal crystal (3 
inches) in a TM Analytic gamma counter (Model 1185). Blood flows were calculated 
by computer using standard equations with appropriate corrections and interference 
coefficients, previously used in this laboratory (2,7,19). The following equation was 
used to calculate blood flow: MBF = (Ct/TW) x (RBW/Cb), where MBF = 
myocardial blood flow in ml/min/g, Ct = tissue radioactivity in counts/min, TW = 
weight of tissue sample in grams, RBW = reference blood withdrawal rate in ml/min, 
and Cb = total radioactivity in reference blood sample. 
3. Data Analysis 
Flows were expressed in ml/min/100 g tissue. Rate-pressure product was 
calculated from heart rate and mean arterial pressure measurements taken immediately 
prior to the injection of the radiolabeled microspheres. Coronary vascular resistance 
was calculated from arterial blood pressure and myocardial blood flow. An analysis 
of variance (ANOV A) with repeated measures was used to test for changes in heart 
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rate, arterial pressure, the double product, coronary blood flow and coronary vascular 
resistance during norepinephrine or saline infusion. A t-test with a Bonferroni 
correction was used to isolate differences. A two-way ANOV A was used to test for 
differences between groups. Values of p < 0.05 were considered statistically 
significant. 
C. RESULTS 
There were no differences in control measurements between SAL-A and NE4-
A for L V blood flow, coronary vascular resistance, mean arterial pressure, heart rate 
and rate-pressure product (Tables 7-1 and 7-2). Control RV flows of 161.1 + 13.2 
ml/min/100 g for SAL-A and 146.8 ± 33.2 ml/min/100 g for NE4-A were not 
different. 
During saline infusion, there were no significant changes in blood flow to the 
LV (Table 7-1) or RV. Additionally, coronary vascular resistance, mean arterial 
pressure and heart rate were not different (Table 7-2). Epicardial, endocardial and 
total L V blood flows were significantly increased at 40 minutes of NE infusion 
compared to control and SAL-A. Right ventricular flow was also increased to 240.9 
+ 35.5 ml/min/100 g (p<0.05). Coronary vascular resistance was decreased 
slightly, but insignificantly at 40 minutes infusion. Mean arterial pressure in NE4-A 
was elevated at 40 minutes infusion compared to control and SAL-A while heart rate 
was depressed. Rate pressure product increased slightly, but insignificantly, in NE4-
A by 40 minutes. By one hour post infusion, myocardial blood flows, arterial 
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TABLE 7-1 
REGIONAL BLOOD FLOW VALUES (ML/MIN/100 G) 
AND CORONARY VASCULAR RESISTANCE (mmHg*ML/MIN/100 G) 
LV LY-ENDO LV-EPI CVR 
CONTROL 
SAL-A 223.6 216.1 231.0 0.36 
± 16.8 + 25.6 + 19.1 + .03 
NE4-A 242.3 256.0 228.5 0.39 
± 47.0 ± 49.1 + 45.0 + .09 
40 MINUTES 
SAL-A 243.0 270.5 215.5 0.38 
+ 35.7 ± 45.3 + 31.1 ± .06 
NE4-A 395.1 *#° 450.0*#° 340.6*#° 0.27 
± 37.0 ± 37.3 ± 39.9 ± .02 
1 HOUR POST INFUSION 
SAL-A 263.5 290.8 241.9 0.30 
+ 25.0 ± 26.8 ± 24.0 ± .03 
NE4-A 228.5 248.4 208.4 0.32 
+ 13.9 ± 14.6 ± 14.6 ± .03 
2 DAYS POST INFUSION 
NE4-C 240.2 232.0 248.4 0.35 
± 29.5 + 29.0 + 33.2 ± .04 
Myocardial blood flow (ml/min/lOOg) for the left ventricle (L V) during a 
40 minute infusion of saline (SAL-A) or 4 µg/kg/min norepinephrine (NE4-A). 
Blood flow was measured in a third group (NE4-C) two days after norepinephrine 
infusion. Left ventricular blood flow was separated into endocardial (LY-ENDO) 
and epicardial (LV-EPI) flows. CVR, coronary vascular resistance in 
mmHg*ml/min/100 g. Data is presented as means + SEM. * p<0.05 compared 
to SAL-A,# p<0.05 compared to control, and O p<0.05 compared to 1 hour post. 
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TABLE 7-2 
ARTERIAL PRESSURE, HEART RA TE AND RA TE-PRESSURE 
PRODUCT DURING SALINE OR NOREPINEPHRINE INFUSION AND AT 
TWO DAYS POST INFUSION 
MAP HR RPP 
CONTROL 
SAL-A 77.7 285.2 22059.6 
± 3.9 ±14.6 ±1265.4 
NE4-A 80.8 293.3 23635.8 
± 2.4 ±11.9 + 853.1 
40 MINUTES 
SAL-A 79.1 278.9 22063.2 
± 5.5 ±13.4 + 1795.5 
NE4-A 104.5*1o 245.8*#o 25626.7 
+ 2.9 ±16.9 ± 1682.9 
1 HOUR POST INFUSION 
SAL-A 75.9 284.5 21761.1 
+ 4.5 ±17.9 ±2035.0 
NE4-A 72.0 279.6 20180.7 
± 5.1 ±11.7 + 1754.7 
2 DAYS POST INFUSION 
NE4-C 78.8 305.0 24055.0 
+ 1.2 ± 6.4 ± 796.5 
Values for mean arterial pressure (MAP, mmHg), heart rate (HR, 
beats/min) and rate pressure product (RPP, mmHg*beats/min) are expressed as 
means± SEM. Abbreviations as in Table 7-1. * p<0.05 compared to SAL-A, 
# p < 0.05 compared to control, and O p < 0.05 compared to 1 hour post infusion. 
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pressures, heart rates and the rate-pressure products were not different than control 
values. Similarly, LV myocardial blood flow and coronary vascular resistance at two 
days post NE infusion were not different than NE4-A at one hour post infusion. 
D. DISCUSSION 
Several investigators have observed a biphasic response in coronary vascular 
resistance and blood flow after the administration of NE in the conscious dog (13,22). 
Initially, there was a brief coronary vasodilation with increased myocardial flow. This 
was followed by a sustained increase in coronary resistance and decrease in coronary 
blood flow (9,22). 
A decrease in myocardial blood flow, particularly to the subendocardium, with 
a prolonged infusion of catecholamines or the administration of high dose 
catecholamines has been reported (4,21,27). Simons and Downing (21) showed an 
initial increase in coronary blood flow in the rabbit during a NE infusion (3 
µg/kg/min) followed by a significant reduction in flow at 40 minutes. Collins and 
Billings (4) reported that ISO injection decreased blood flow to the LV 
subendocardium of the rat. Similar results were reported in the dog after ISO 
administration (8). In the isolated, supported canine heart, an intracoronary infusion 
of NE reduced blood flow to the endocardium (27). The decreased flows were 
attributed to a-receptor mediated coronary vasoconstriction (21) or the underperfusion 
of the endocardium due to mechanical forces (4). It has been further hypothesized 
167 
that the depressed myocardial flow was a mechanism of catecholamine-induced cardiac 
injury. 
In contrast, Moir and DeBra ( 17) have shown a 64 % increase in total coronary 
blood flow with a slightly greater increase in endocardial flow with NE administration 
in the dog. The result presented in this chapter demonstrate a significant increase in 
myocardial blood flow with a 40 minute NE infusion. The discrepancy in the findings 
may be due to the catecholamine used, dose administered in each study or an 
undetermined factor. Collins and Billing (4) and Fortuin et al. (8) administered ISO, 
a potent /3-agonist, while Moir and DeBra administered NE, a mixed al/3 agonist. 
The effects of ISO on coronary blood flow were prevented by /3-receptor blockade (4). 
When Fortuin et al. (8) administered NE in the presence of propranolol, endocardial 
flow was significantly augmented. 
In the present study, endocardial, epicardial and total L V flows were increased 
and coronary vascular resistance was decreased at 40 minutes NE infusion in the 
rabbit (4 µg/kg/min). These results provided no evidence to support the hypothesis 
that a 40 minute NE infusion induced coronary vasoconstriction. A relatively 
unchanged rate-pressure product, an index of myocardial oxygen demand, coupled 
with a 63 % increase in L V blood flow, also suggested the myocardium was not 
hypoxic during NE infusion. Further study is needed to determined if NE infusion 
of a longer duration or higher dosage results in ischemic injury and a defective 
reperfusion of the myocardium. 
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CHAPTER VIII 
SUMMARY 
1. A 90 minute infusion of high dose norepinephrine in the rabbit acutely 
impairs left ventricular diastolic and systolic function. 
2. Systolic function improved within 48 hours after norepinephrine infusion 
whereas diastolic function remained depressed. 
3. Myocardial responsiveness to ex- or /3-adrenergic receptor activation was not 
altered acutely or chronically after norepinephrine administration. 
4. The administration of cx-tocopherol and selenium every other day for two 
weeks did not protect the rabbit myocardium from norepinephrine-induced 
injury. 
5. Coronary blood flow was significantly increased in the left and right 
ventricular myocardium at the end of a 40 minute, high dose norepinephrine 
infusion. Myocardial blood flow returned to control levels by one hour 
post infusion. 
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CHAPTER IX 
CONCLUSIONS 
The myocardial lesions produced when the heart was exposed to excessive 
catecholamines have been intensely studied and characterized by numerous 
investigators. Alterations in cardiac function following catecholamine-induced injury, 
however, have not been fully investigated. 
Ventricular function studies utilizing rat and rabbit models of catecholamine-
induced cardiac injury indicated that systolic function was depressed forty-eight hours 
after catecholamine administration. In the first study of this dissertation, it was 
hypothesized that cardiac function was impaired acutely after catecholamine injury and 
some functional recovery occurred by 48 hours. To test this hypothesis, left 
ventricular function was measured immediately after a 90 minute norepinephrine (NE) 
infusion and at two days post infusion. To further characterize functional alterations, 
myocardial function was assessed at three levels of norepinephrine-induced injury. 
This study is the first to demonstrate impairment in left ventricular systolic 
function of rabbit hearts acutely after norepinephrine injury with significant 
improvement by 48 hours, except in hearts with the most severe injury. Additionally, 
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this study is the first to report diastolic function in norepinephrine cardiomyopathy. 
Diastolic function, as measured by LV -dP/dt and tau, was impaired but unlike 
systolic function, the dysfunction observed immediately after the 90 minute NE 
infusion were still present at two days. 
Depression in systolic function observed in norepinephrine-induced 
cardiomyopathy may be due to a loss of functional myocytes. Histological 
examination of the myocardium reveals the hypercontraction of sarcomeres and the 
loss of myofilament structure in some myocytes. The loss of normal structure of 
contractile elements reduces contractile function in those cells. Damage of a critical 
number of cardiac myocytes could depress systolic function of the entire myocardium. 
To date, there is no direct evidence that the myofilaments in cells with normal 
histology are injured. If the contractile elements are defective and function 
abnormally, even normal appearing cells would contribute to the impairment in 
systolic and possibly diastolic function observed in catecholamine cardiomyopathy. 
Multiple factors may contribute to diastolic dysfunction. In the initiation of 
contraction, calcium moves into a myocyte through ion channels and is released by 
the sarcoplasmic reticulum so intracellular calcium concentration increases. If the cell 
is functioning normally, the calcium is later extruded via the sodium-calcium exchange 
and calcium pump or transported into the sarcoplasmic reticulum. The decrease in 
cytosolic calcium levels allows the muscle to relax. In catecholamine injury, removal 
of calcium from the cytosol is impaired. The sodium-calcium exchange and calcium 
pump activities are depressed so calcium is not extruded from the cell. Additionally, 
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the uptake of calcium by the sarcoplasmic reticulum is impaired. These defects allow 
intracellular calcium levels to rise. High cytosolic calcium concentrations coupled 
with impaired removal of calcium may contribute to the decreased rate of ventricular 
relaxation. Cellular degeneration and myocardial edema, characteristic signs of 
catecholamine injury, increase myocardial stiffness and may augment the diastolic 
dysfunction seen in norepinephrine-induced cardiomyopathy. 
Exposure of the myocardium to catecholamines decreases the responsiveness 
of the adrenergic receptor system to subsequent stimulation (4,6). This process is 
known as desensitization. In the second study (Chapter V), it was hypothesized that 
the /j-adrenergic receptor would be desensitized during the NE infusion. Stimulation 
of the isolated heart by a /j-receptor agonist would then elicit smaller changes in 
ventricular function. It was also proposed that the changes in ventricular function 
with a-adrenergic receptor activation would be more important after NE induced 
injury. 
Although adenylate cyclase activity was not measured directly, the results 
presented in Chapter V indicate the /j-receptor was not uncoupled from adenylate 
cyclase. Beta-receptor stimulation by dobutamine increased function in NE pretreated 
hearts the same amount as hearts from saline treated rabbits with one interesting 
exception. In acute experiments, the ability of /j-receptor stimulation to increase L V 
+dP/dt in hearts injured by NE was impaired. It was hypothesized that the NE 
infusion acutely altered a step in cross-bridge formation or cycling. The ability of NE 
injured hearts to increase LV +dP/dt with /j-receptor activation was slightly improved 
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at 48 hours. The responsiveness of the a-adrenergic receptor to agonist stimulation 
was not changed following NE administration. 
The pathogenesis of catecholamine cardiomyopathy involves multiple 
mechanisms. Several investigators have reported that toxic metabolites of 
catecholamine autoxidation induce myocardial injury (3,9, 11). These metabolites, 
particularly the free radicals may initiate lipid peroxidation which alters membrane 
permeability and function. 
The third study (Chapter VI) was designed to test whether pretreatment with 
a-tocopherol and selenium protected hearts from norepinephrine-induced injury. a-
Tocopherol is an antioxidant located in cellular membranes. Selenium is an essential 
component of glutathione peroxidase, an enzyme which removes lipid peroxides from 
membranes before the peroxides damage the membrane. It was hypothesized that if 
metabolites of NE autoxidation are acting as membrane oxidants, increasing the anti-
oxidant capacity of the heart would protect the myocardium from NE injury. The 
results of this study suggest however, that NE injury in the rabbit heart is not 
produced by oxidative damage. Pretreatment with a-tocopherol and selenium did not 
reduce the diastolic or systolic dysfunction which occurred with the administration of 
high dose NE. 
One alternative explanation is that the oxidative capacity of the heart was 
exceeded by the dose of NE administered eventhough rabbits were pretreated with a-
tocopherol and selenium. The oxidants produced by NE oxidation would then damage 
the myocardium unhindered. Another explanation is that a-tocopherol administered 
176 
with selenium is not the most effective combination of anti-oxidants. The protective 
effects of a-tocopherol and selenium may be species specific. Further investigation 
is needed to determine if a-tocopherol administered alone or in combination with 
another antioxidant protects the rabbit myocardium from NE-induced injury. 
Alpha-receptor mediated coronary vasoconstriction with the administration of 
catecholamines is well documented (1,2,7). It has been proposed that high levels of 
circulating catecholamines produce coronary vasoconstriction with localized ischemia 
with the ischemic insult injuring the myocardium (8). If the cardiomyopathy induced 
by high dose catecholamines is the result of ischemia, perfusion abnormalities similar 
to those observed in models of temporary ischemia, may develop. 
In the final study of this dissertation (Chapter VII), catecholamine induced 
coronary vasoconstriction or ischemia was not observed at 40 minutes of NE infusion. 
In fact, endocardial, epicardial and total left ventricular blood flows were elevated 
significantly while coronary vascular resistance was reduced slightly. Perfusion 
abnormalities were not apparent. This data does not support the hypothesis that NE 
injury is secondary to coronary vasoconstriction and/or ischemia. The increase in 
blood flow coupled with only a small change in rate-pressure product also suggest that 
the myocardium was not hypoxic during the NE infusion. 
The administration of catecholamines initially increases myocardial blood flow 
and is quickly followed by an a-receptor mediated coronary vasoconstriction and a 
decrease in coronary blood flow (5,10). The effects of administering catecholamines 
for longer periods on myocardial blood flow has not been thoroughly investigated. 
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The data presented in Chapter VII suggests that myocardial blood flow increases again 
with prolonged exposure to a catecholamine. With time, metabolic factors may over-
ride cx-vasoconstriction and induce coronary vasodilation. 
In summary, it is clear that a few questions regarding ventricular dysfunction 
which occurs following the administration of high dose NE have been answered. Left 
ventricular function of rabbit hearts is depressed acutely after norepinephrine injury 
with significant improvement by 48 hours, except in hearts with the most severe 
injury. Diastolic function was impaired but unlike systolic function, the dysfunction 
observed immediately after the 90 minute NE infusion was still present at two days. 
Further investigation is needed into the time course of recovery of diastolic function, 
if indeed it does completely recover. Similarly, it would be interesting to determine 
if hearts damaged by the highest NE dose (6 µg/kg/min) gradually recovered 
ventricular systolic and diastolic function. Mechanisms of catecholamine-induced 
myocardial injury also need further study. The exact role of metabolites of 
catecholamine autoxidation in the pathogenesis of catecholamine cardiomyopathy 
remains to be elucidated. Likewise, the time course of changes in myocardial blood 
flow during a prolong catecholamine infusion needs to be determined. 
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